



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/38, C07K 14/045, A61K 39/245, C12N 15/86 // A61K 31/70		A1	(11) International Publication Number: WO 97/40165
			(43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/US97/06866		(74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).	
(22) International Filing Date: 22 April 1997 (22.04.97)			
(30) Priority Data: 60/015,717 23 April 1996 (23.04.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 60/015,717 (CIP) Filed on 23 April 1996 (23.04.96)		Published With international search report. With amended claims and statement.	
(71) Applicant (for all designated States except US): THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 3601 Spruce Street, Philadelphia, PA 19104 (US).		Date of publication of the amended claims and statement: 8 January 1998 (08.01.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): GONCZOL, Eva [US/US]; Radnor House, Apartment 916, 1030 E. Lancaster Avenue, Rosemont, PA 19010 (US). BERENCSI, Klara [HU/US]; Apartment 327, 1030 E. Lancaster Avenue, Rosemont, PA 19010 (US). KARI, Csaba [HU/US]; Apartment 327, 1030 E. Lancaster Avenue, Rosemont, PA 19010 (US).			
(54) Title: NOVEL HUMAN CYTOMEGALOVIRUS DNA CONSTRUCTS AND USES THEREFOR			
(57) Abstract			
<p>Novel DNA molecules for <i>in vitro</i> and <i>in vivo</i> expression of HCMV gB, gB transmembrane-deleted derivatives, pp65, pp150, and IE-exon-4 proteins are described. Preferably, the molecules are plasmids. Also described are methods of using these DNA molecules to induce immune responses to HCMV, and the use of a plasmid of the invention to prime immune responses to HCMV vaccines.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL HUMAN CYTOMEGALOVIRUS DNA CONSTRUCTS
AND USES THEREFOR

Field of the Invention

This invention relates generally to compositions
5 useful in preventing and treating human cytomegalovirus
infection.

Background of the Invention

Cytomegalovirus (CMV) is one of a group of highly
host specific herpes viruses that produce unique large
10 cells bearing intranuclear inclusions. The envelope of
the human cytomegalovirus (HCMV) is characterized by a
major glycoprotein complex termed gB or gCI, which was
previously referred to as gA.

Infection with HCMV is common and usually
15 asymptomatic. However, the incidence and spectrum of
disease in newborns and immunocompromised hosts
establishes this virus as an important human pathogen.
HCMV has also been suggested to be an important co-factor
in the development of atherosclerosis and restenosis
20 after angioplastic surgery.

Several HCMV vaccines have been developed or are in
the process of development. Vaccines based on live
attenuated strains of HCMV have been described. [See,
e.g., S. A. Plotkin et al, Lancet, 1:528-30 (1984); S. A.
25 Plotkin et al, J. Infect. Dis., 134:470-75 (1976); S. A.
Plotkin et al, "Prevention of Cytomegalovirus Disease by
Towne Strain Live Attenuated Vaccine", in Birth Defects,
Original Article Series, 20(1):271-287 (1984); J. P.
Glazer et al, Ann. Intern. Med., 91:676-83 (1979); and U.
30 S. Patent 3,959,466.] A proposed HCMV vaccine using a
recombinant vaccinia virus expressing HCMV glycoprotein B
has also been described. [See, e.g., Cranage, M. P. et
al, EMBO J., 5:3057-3063 (1986).] However, vaccinia
vaccines are considered possible causes of encephalitis.
35 Other recombinant HCMV vaccines have been described.

See, e.g., G. S. Marshall et al, J. Infect. Dis., 162:1177-1181 (1990); K. Berencsi et al, J. Gen. Virol., 74:2507-2512 (1993), which describe adenovirus-HCMV recombinants.

- 5 There remains a need in the art for additional compositions useful in preventing CMV infection by enhancing immune responses to HCMV vaccines and generating neutralizing antibody and/or cellular responses to CMV in the human immune system.

10 Summary of the Invention

The present invention provides a series of DNA molecules expressing human cytomegalovirus (HCMV) genome fragments, which are particularly useful in inducing HCMV-specific immune responses.

- 15 Thus, in one aspect, the invention provides a DNA molecule which is non-replicating in mammals and which comprises at least one human cytomegalovirus antigen which is operably linked to regulatory sequences which express the antigen in the mammal. Advantageously, the antigen elicits an immune response in said mammal. In
20 one preferred embodiment, the DNA molecule is a plasmid.

- In another aspect, the invention provides a plasmid, pTet-gB, containing the portion of the HCMV genome (UL55) encoding gB. This plasmid further contains a
25 tetracycline regulatable HCMV-immediate early promoter, which is useful in controlling expression of gB. Another plasmid of the invention encoding the full-length gB subunit protein is a pARC-gB plasmid.

- Yet another plasmid of the invention, pARC-gB₆₈₀,
30 contains the portion of the HCMV genome encoding the N-terminal 680 amino acids of the gB protein (gB₁₋₆₈₀).

The pARC-pp65 plasmid of the invention contains the portion of the HCMV genome (UL83) encoding the HCMV pp65 tegument protein. The pARC-pp150 plasmid contains the

portion of the HCMV genome (UL32) encoding the HCMV pp150 tegument protein.

5 The p Δ RC-exon-4 contains the portion of the HCMV genome (truncated UL123) encoding HCMV immediate-early (IE) exon-4.

In yet another aspect, the present invention provides an immunogenic composition of the invention comprising at least one of the DNA molecules of the invention and a carrier.

10 In still another aspect, the present invention provides a method of inducing HCMV-specific immune responses in an animal by administering to the animal an effective amount of an immunogenic composition of the invention. Preferably, this composition contains p Δ RC-gB₆₈₀, pTet-gB and/or p Δ RC-pp65.

15 In yet a further aspect, the present invention provides a method of priming immune responses to a selected human cytomegalovirus immunogenic composition by administering an immunogenic composition of the invention prior to administration of the second immunogenic or vaccine composition.

20 Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

25 Brief Description of the Drawings

Fig. 1 illustrates the construction of the pTet-gB plasmid.

Fig. 2 is a graph illustrating the results of pp65-specific CTL responses in BALB/c mice immunized with p Δ RC-pp65. The circle represents VacWR-pp65-infected MC57 (MHC-mismatched) target cells; the diamond represents WT-Vac-infected P-815 cells; and the square represents VacWR-pp65-infected P-815 (MHC-mismatched) target cells.

Fig. 3A-3E provides the full-length DNA and amino acid sequences [SEQ ID NO:1 and 2] of a human cytomegalovirus virus gB gene.

Fig. 4A - B provide the full-length DNA and amino acid sequences [SEQ ID NO:3 and 4] of a human cytomegalovirus immediate-early exon-4.

Fig. 5 provides the full-length DNA and amino acid sequences of a human cytomegalovirus phosphoprotein (pp) 65 gene Towne strain on the top line [SEQ ID NO: 5 and 6], and, on the bottom line, the sequence of the pp65-AD169 strain where it differs from the Towne strain [SEQ ID NO: 7 and 8].

Fig. 6A - B provide the full-length DNA and amino acid sequences [SEQ ID NO: 9 and 10] of a human cytomegalovirus phosphoprotein (pp) 150 gene, AD169 strain.

Fig. 7A provides a circular map of the eukaryotic expression vector pCB11.

Fig. 7B provides a circular map of pCBgB.

Fig. 7C provides a circular map of pCBgB Δ tm.

Fig. 8 provides a schematic representation of the gB protein (top line) and of its homolog which is deleted of the transmembrane domain (bottom line).

Fig. 9 is a graph illustrating the anti-gB titers in sera of BALB/c mice immunized with plasmids pCBgB and pCBgB Δ tm intramuscularly (IM) and intradermally (ID).

Detailed Description of the Invention

The present invention provides DNA molecules useful for *in vitro* and *in vivo* expression of antigenic fragments of the HCMV genome. Particularly desirable antigens include full-length and transmembrane-deleted fragments of gB such as gB₁₋₆₈₀, pp65, pp150, and IE-exon-4. Preferably, the DNA molecules of the invention are plasmids. The inventors have found that these DNA

molecules induce HCMV-specific immune responses, including ELISA and neutralizing antibodies and cytotoxic T lymphocytes (CTL), and are further useful in priming immune responses to subsequently administered HCMV immunogens and vaccines.

Thus, in one embodiment, the present invention provides a DNA molecule containing at least one HCMV antigen under the control of regulatory sequences which express the antigen in vivo or in vitro. Desirably, the DNA molecule is incapable of replicating in mammals. In a particularly desirable aspect of this embodiment, the DNA molecule is a plasmid.

As defined herein, an HCMV antigen includes a portion of the HCMV genome or a protein or peptide encoded thereby which induces an immune response in a mammal. Desirably, the immune response induced is HCMV-specific and protective. However, non-protective immune responses are also useful according to the invention, e.g., for priming immune responses. Currently, preferred HCMV antigens include full-length gB, a fragment or derivative of gB which lacks at least the transmembrane domain, pp65, pp150, and the immediate-early exon-4. Other suitable antigens may be readily selected by one of skill in the art.

The exemplary DNA molecules of invention, described herein, have been constructed using gene fragments derived from the Towne strain of HCMV. The Towne strain of HCMV, is particularly desirable because it is attenuated and has a broad antigenic spectrum. This strain is described in J. Virol., 11 (6): 991 (1973) and is available from the ATCC under accession number VR-977. The Ad169 strain is also available from the ATCC, under accession number VR-538. However, other strains of CMV useful in the practice of this invention may be obtained

from depositories like the ATCC or from other institutes or universities, or from commercial sources.

Thus, the CMV gene fragment encoding the desired protein (e.g., gB, pp65, pp150) or protein fragment (e.g., gB₁₋₆₈₀ or IE-exon-4) may be isolated from known HCMV strains. See, e.g., Mach et al, J. Gen. Virol., 67:1461-1467 (1986); Cranage, M. P. et al, EMBO J., 5:3057-3063 (1986); and Spaete et al, Virol., 167:207-225 (1987), which provide isolation techniques. For example, using a known HCMV sequence, the desired HCMV gene or gene fragment [e.g., pp65 (UL83)] is PCR amplified, isolated, and inserted into the plasmid vector or other DNA molecule of the invention using known techniques. Alternatively, the desired CMV sequences can be chemically synthesized by conventional methods known to one of skill in the art, purchased from commercial sources, or derived from CMV strains isolated using known techniques.

If desired, the DNA molecules of the invention may contain multiple copies of the HCMV gene or gene fragment. Alternatively, the recombinant plasmid may contain more than one HCMV gene/gene fragment, so that the plasmid may express two or more HCMV proteins. For example, as shown herein, the presence of both gB- and pp65-specific ELISA antibodies and pp65-specific CTL in the mice inoculated with pTet-gB and pARC-pp65 in a mixture indicates that gB and pp65 do not mutually block antigen presentation or B and T cell stimulation when expressed in the same cells or in close proximity. Thus, gB (or gB₆₈₀) and pp65 proteins are particularly well suited for incorporation into a plasmid which expressed both protein (termed herein a chimeric vector). Thus, one particularly desirable embodiment of the present invention provides a DNA molecule containing the gB and the pp65 antigens. In another particularly desirable

embodiment, the DNA molecule contains a transmembrane-deleted gB fragment or derivative (e.g, gB₆₈₀ or gB Δ tm) and the pp65 antigens.

5 In the construction of the DNA molecules of the invention, one of skill in the art can readily select appropriate regulatory sequences, enhancers, suitable promoters, secretory signal sequences and the like. In the examples below, the plasmids have been provided with a tetracycline repressor from *E. coli*. However, if
10 desired, the plasmid or other DNA molecule may be engineered to contain another regulatable promoter, which "turns on" expression upon administration of an appropriate agent (e.g., tetracycline), permitting regulation of *in vivo* expression of the HCMV gene
15 product. Such agents are well known to those of skill in the art. The techniques employed to insert the HCMV gene into the DNA molecule and make other alterations, e.g., to insert linker sequences and the like, are known to one of skill in the art. See, e.g., Sambrook et al,
20 "Molecular Cloning. A Laboratory Manual" (2d edition), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).

In one embodiment, the DNA molecules of the invention are plasmids. One exemplary plasmid is pTet-
25 gB. Construction of this plasmid is described in more detail below. Plasmid TetotTA-gB contains the gene from HCMV (the unique long (UL) 55) encoding the full-length gB subunit protein and a tetracycline regulatable HCMV-immediate early promoter which controls expression of gB.
30 For convenience, the sequences of the HCMV gene fragment encoding the full-length gB protein which were used in the examples below are provided in Fig. 3A-3E [SEQ ID NO: 1 and 2]. As discussed herein, this invention is not limited to this strain of HCMV. pTet-gB has been found
35 to be useful alone, and in conjunction with the other DNA

molecules of the invention, and particularly the p Δ RC-pp65 plasmid described below. pTet-gB is also particularly useful for priming immune responses to subsequently administered HCMV immunogenic compositions and vaccines.

The pTetotTA-gB plasmid has been deposited pursuant to the Budapest Treaty, in the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, U.S.A. This deposit, designated ATCC 98029, was made on April 23, 1996 and is termed herein, pTet-gB.

Other plasmids provided herein, p Δ RC-gB and pCBgB, also contain the HCMV gene encoding the gB protein. As demonstrated below, these DNA plasmids have been found to be highly potent immunogens for HCMV. See Examples 8 and 14.

Another plasmid of the invention, p Δ RC-gB₆₈₀ contains the portion of the HCMV gene encoding the N-terminal 680 amino acids of the gB protein and is capable of expressing this fragment *in vivo* or *in vitro*. This gB fragment is designated herein gB₁₋₆₈₀. As illustrated in Figure 3A-E [SEQ ID NO:2], the full-length gB subunit protein consists of 907 amino acids. This plasmid, which expresses a secreted form of gB, has been found to be a more potent immunogen than the plasmids expressing the full-length gB.

Also provided herein is plasmid pCDgB Δ tm, which contains a deletion of the gB transmembrane region. This plasmid has been found to induce HCMV-specific neutralizing antibodies (see Example 14) and to be a more potent immunogen than the corresponding DNA plasmid encoding full-length gB.

Plasmid p Δ RC-exon-4 plasmid contains the portion of the HCMV immediate-early (IE) gene encoding HCMV IE-exon-4 and is capable of expressing the gene product. The HCMV IE-exon-4 gene fragment has been described in

international patent application PCT/US94/02107,
published August 18, 1994, which is incorporated by
reference herein. The IE gene and the intron/exon
junctions for Towne strain HCMV are provided in Stenberg
5 et al, J. Virol., 49:190-199 (1984), and are available
from GenBank under accession number K01484, M11828-30.
The sequences of the IE-exon-4 gene fragment, Towne
strain, are provided in Fig. 4A - B [SEQ ID NO: 3 and 4],
for convenience. This invention is not limited to the
10 use of the IE-exon-4 sequences from this viral strain.

Plasmid pARC-pp65 contains the HCMV gene encoding
the HCMV phosphoprotein (pp) 65 tegument protein and is
capable of expressing pp65 *in vivo* or *in vitro*. As
described herein, immunization with pARC-pp65 induced a
15 reduction of virus titers in the mouse lung after
intranasal challenge with vaccinia recombinants carrying
the pp65 gene, suggesting the protective function of
cell-mediated immunity in lung after DNA immunization.
Further, in contrast to a prior art pp65-containing
20 plasmid construct which induced ELISA antibodies in only
about 60% of inoculation mice, nearly 100% of mice
inoculated with pARC-pp65 responded with pp65-specific
ELISA antibodies. The sequences of the pp65 gene, Towne
and AD169 strains, have been described in H. Pande et al,
25 Virol., 181(1):220-228 (1991) and are provided in Fig. 5
[SEQ ID NO: 5 - 8] for convenience. pp65 sequences may
be readily isolated using known techniques from other
HCMV strains, or obtained from commercial sources. The
strain from which the pp65 sequences are derived is not a
30 limitation on the present invention.

Plasmid pARC-pp150 contains the portion of the HCMV
gene encoding the HCMV pp150 tegument protein and is
capable of expressing pp150 *in vivo* or *in vitro*. The
sequences of the pp150 gene, Ad169 strain, have been
35 described in G. Jahn et al, J. Virol., 61(5):1358-1367

(1987) and are provided in Fig. 6A - B for convenience [SEQ ID NO: 9 and 10]. pp150 sequences may be readily isolated using known techniques from another HCMV strain, or obtained from commercial sources. The strain from
5 which the pp150 sequences are derived is not a limitation on the present invention.

The DNA molecules, and particularly the plasmids described herein, may be used for expression of the gB, gB₁₋₆₈₀ fragment, pp65, pp150, or IE-exon-4 *in vitro*. The
10 molecules are introduced by conventional means into the desired host cell [see, Sambrook et al, cited above]. Suitable host cells include, without limitation, bacterial cells, mammalian cells and cell lines, e.g., A549 (human lung carcinoma) or 293 (transformed human
15 embryonic kidney) cells.

The host cell, once transfected with the recombinant plasmid (or other DNA molecule) of the present invention, is then cultured in a suitable medium, such as Minimal Essential Medium (MEM) for mammalian cells. The culture
20 conditions are conventional for the host cell and allow the expressed HCMV protein, e.g., gB, to be produced either intracellularly, or secreted extracellularly into the medium. Conventional protein isolation techniques are employed to isolate the expressed subunit from the
25 selected host cell or medium.

Alternatively, transfected host cells are themselves used as antigens, e.g., in *in vitro* immunological assays, such as enzyme-linked immunosorbent assays (ELISA). Such assay techniques are well known to those of skill in the
30 art.

In yet another embodiment, one or more of the DNA molecules (e.g., plasmids) described herein may be used directly as immunogens in an immunogenic composition or directly for priming the immune response to a
35 subsequently administered immunogenic or vaccine

composition. According to this embodiment of the invention, the DNA molecule (e.g., plasmid) containing the HCMV gene or gene fragment is introduced directly (i.e., as "naked DNA") into the animal by injection. The DNA molecule of the invention, when introduced into an animal, transfects the host's cells and produces the CMV protein in those cells. Methods of administering so-called 'naked DNA', are known to those of skill in the art. [See. e.g., J. Cohen, Science, 259:1691-1692 (March 19, 1993); E. Fynan et al, Proc. Natl. Acad. Sci., 90:11478-11482 (Dec. 1993); J. A. Wolff et al, Biotechniques, 11:474-485 (1991); International Patent Application PCT WO94/01139, which are incorporated by reference herein for purposes of described various 'naked DNA' delivery methods.]

The preparation of a pharmaceutically acceptable immunogenic composition, having appropriate pH, isotonicity, stability and other conventional characteristics is within the skill of the art.

Currently, in a preferred embodiment, one or more of the recombinant plasmids (or other DNA molecules) of the invention is suspended in an acceptable carrier such as isotonic water, phosphate buffered saline, or the like. Optionally, although currently less preferred, such a composition may contain other components, such as adjuvants, e.g., aqueous suspensions magnesium hydroxides.

An effective amount of an immunogenic composition of the invention preferably contains between 10 μ g and 10 mg, and preferably between about 80 μ g and 150 μ g of DNA of the invention per inoculation. Desirably, for each inoculation, the DNA of the invention is formulated in about 100 μ l of a suitable carrier. In a particularly preferred embodiment, each patient is administered 100 μ g DNA, which is administered three times at about 4 week

intervals. Alternatively, the dosage regimen involved in the method for immunizing with the recombinant DNA molecule (e.g., plasmid) of the present invention can be determined considering various clinical and environmental factors known to affect vaccine administration. For example, following a first administration of an immunogenic composition of the invention, boosters may be administered approximately 2- to 15-weeks later. These boosters may involve an administration of the same immunogenic composition as was first administered, or may involve administration of an effective amount of another immunogenic composition of the invention. Additional doses of the vaccines of this invention may also be administered where considered desirable by the physician.

In another aspect, the present invention provides a method of inducing HCMV-specific immune responses in an animal. The method involves administering to an animal an effective amount of an immunogenic composition containing one or more of the DNA molecules of the invention, as described above. The immunogenic composition is administered by any suitable route, including oral, nasal routes, subcutaneous and intraperitoneal. However, currently preferred are the intramuscular and intradermal routes of administration.

In a particularly preferred embodiment of this aspect, the method of inducing an HCMV-specific immune response of the invention involves the administration of one or more immunogenic compositions of the invention. These compositions may be formulated so as to contain a single DNA molecule of the invention, or may contain mixtures of the DNA molecules of the invention. In one desirable embodiment, the composition contains p Δ Rc-gB₆₈₀ or pCBgB Δ tm. In another desirable embodiment, the composition contains a plasmid containing pp65 according to the invention. As illustrated in the examples below,

administration of pARC-pp65 has been found to induce a potent HCMV-specific immune response. In another desirable embodiment of the invention, the combined administration of pTet-gB and pARC-pp65 invention (which
5 may be formulated in a single composition, or preferably, administered separately) induces potent HCMV-specific ELISA and neutralizing antibodies to both proteins. In yet another desirable embodiment, the present invention provides a composition containing a chimeric plasmid
10 which expresses pp65 and gB₆₈₀ or gB. Yet another desired embodiment involves combined administration of pARC-gB₆₈₀ and pARC-pp65.

In another aspect of this invention, a method of priming immune responses to a human cytomegalovirus
15 immunogenic or vaccinal composition is provided. This method involves administering an immunogenic composition of the invention prior to administration of a second immunogenic or vaccinal composition. Desirably, an effective amount of an immunogenic composition of the
20 invention, e.g., containing pTet-gB, is administered between about 4 and 15 weeks prior to administration of the immunogenic or vaccinal composition. The second immunogenic or vaccinal composition, for which the immune response is enhanced or primed by the method of the
25 invention, may be an immunogenic composition of the invention or a conventional immunogenic or vaccine composition. For example, such a composition may contain one or more HCMV proteins (e.g., the isolated, purified gB protein described in the examples below), a whole
30 virus (e.g., semipurified Towne strain HCMV virion), or recombinant HCMV viruses. Suitable recombinant viruses are well known to those of skill in the art and include, e.g., the Ad-gB virus [G. Marshall et al, (1990), cited above, and EP 389 286; the Ad-gB-IE-exon-4 virus [WO
35 94/17810]; the Ad-gB fragment viruses [WO 94/23744].

Other suitable HCMV vaccinal compositions are well known to those of skill in the art.

These examples illustrate the preferred methods for preparing and using the plasmids of the invention. These examples are illustrative only and do not limit the scope of the invention.

Example 1 - Construction of pTet-gB plasmid

The full-length HCMV-gB gene was obtained from the plasmid pAd-gB [Marshall et al., J. Infect. Dis., 162:1177-1181 (1990)] by XbaI-XbaI-digestion.

The full length HCMV-gB was inserted into the plasmid pUHD10-3 [Gossen and Bujard, Proc. Natl. Acad. Sci. USA, 12:5547-5551 (1992)]. This plasmid contains:

- (a) a tetracycline regulatable promoter (HCMV minimal promoter, - 53 relative to the start site, with heptamerized tet-operon derived from the regulatory region of tet^R - gene of transposon -10);
- (b) a multiple cloning site (including an XbaI site); and
- (c) an SV40 polyadenylation signal downstream of the polycloning site.

After inserting the HCMV-gB (referred to as pTet0-gB), the plasmid was digested with Hind III followed by blunt-ending, then digested with PvuI and the fragment containing the tetracycline regulatable promoter-HCMV-gB-SV40 polyA signal sequences was isolated and inserted into the plasmid pUHD15-1 [Gossen and Bujard, cited above]. This latter plasmid (hereafter referred to as ptTA) contains the HCMV-IE promoter-enhancer which constitutively drives the tTA gene followed by the SV40 polyA signal. The tTA-gene codes for a fusion protein consisting of the tetracycline repressor from *E. coli* and the carboxy-terminal 130 amino acids of the herpes simplex virus protein 16 gene (HSV

VP-16). This fusion protein is a powerful transactivator of the tetracycline regulatable promoter of pTeto (which drives the HCMV-gB gene), because of the specific and high affinity attachment of the tetracycline repressor to the tetracycline operator sequences ensures the activation of transcription from the minimal HCMV promoter by the transactivator domain of HSV VP-16 gene (fused to the tetracycline repressor). The gene activation is specific for the pteto promoter. In the presence of low, non-toxic concentration of tetracycline (1 μ g/ml or less), however, the transactivation is switched off, since tetracycline prevents the attachment of the tetracycline repressor to the teto sequences and no or very low gene expression is allowed (i.e., only the minimal HCMV promoter basal activity which is negligible in almost all cell types investigated so far).

To obtain the gB-expression plasmid regulatable by tetracycline, ptTA was cut just upstream of the HCMV-IE promoter/enhancer by *Xho*I, blunt-ended and cut with *Pvu*I. The large fragment containing the HCMV-IE promoter-enhancer-tTA fusion protein gene followed by the SV40 polyA signal and the *E. coli* sequences of the plasmid (i.e., the replication origin and the beta-lactamase genes) were isolated. This isolated fragment was ligated with the fragment of pUHD10-3 containing the gB gene by the competent blunt-end and *Pvu*I ends, resulting in the plasmid pteto-gB-tTA. The resulting plasmid contains both the transactivator and the HCMV-gB gene. The structure of the plasmid is, in addition to the *E. coli*-part, tetracycline-regulatable promoter (7 teto + minimal HCMV promoter) followed by the HCMV-gB gene, followed by the SV40 polyA signal, followed by the HCMV-IE promoter-enhancer, followed by the tTA gene and ending with the SV40 polyA signal.

The tetracycline-controllable expression system has been found to work correctly in vivo in the mouse as well [J. Dhawan et al, Somatic Cell and Molecular Genetics, 21:233-240 (1995)]. The pTet-gB plasmid is suitable to control naked DNA immunization. It is possible to give tetracycline to mice in their drinking water in concentrations not toxic for the animals but reaching sufficient levels able to regulate expression in muscle tissues [J. Dhawan et al., Somatic Cell and Molecular Genetics, 21: 233-240 (1995)]. By tetracycline treatment of transfected cultures or inoculated mice the time of antigen exposure can be manipulated. The silent presence of the inoculated plasmid can be tested. Without tetracycline treatment, however, this plasmid simply serves as a plasmid DNA immunogen or vaccine.

Example 2 - Construction of further Plasmids

A. Construction of pRC-gB

pRC/CMV (Invitrogen Corporation) contains the HCMV-IE promoter. The full length gB gene (XbaI-XbaI fragment from pAd5-gB) was obtained using conventional techniques [SEQ ID NO:1] and inserted into pRC/CMV according to manufacturer's directions. The resulting plasmid is termed herein pRC-gB.

B. Construction of pARC-gB

pARC/CMV was derived from pRC/CMV plasmid by deleting the PvuII 1290 - PvuII 3557 fragment to obtain more unique restriction sites. The full gB [SEQ ID NO:1], derived from the plasmid pAd-gB [Marshall et al., J. Infect. Dis., 162:1177-1181 (1990)], was subcloned using conventional techniques, inserted into pUC-8 (commercially available), then obtained as a HindIII-BamHI fragment and inserted into the HindIII-BamHI digested pARC/CMV vector. The resulting plasmid is termed pARC-gB.

C. Construction of pARC-gB₆₈₀

pARC-gB₆₈₀ expresses the N-terminal 680 amino acids of the gB protein [SEQ ID NO:2]. The plasmid was derived from pARC-gB, by deleting the C-terminal 227 amino acids of the gB by Xho-digestion, Klenow polymerase filling, removing the C-terminal portion of the gB gene, and religation of the 5400 bp fragment. The insert is approximately 2200bp.

Example 3 - Construction of pARC-pp65 and pARC-pp150

10 A. pARC-pp65

The plasmid pARC-pp65, which expresses the pp65 tegument protein of HCMV, was constructed as follows. H. Pande et al, Virology, 182(1):220-228 (1991), which provides the nucleotide sequences of the pp65 gene, is incorporated by reference herein [SEQ ID NO: 5 and 6].

15 The pp65 gene was isolated from the HCMV genome using conventional polymerase chain reaction techniques and inserted into a suitable expression plasmid. In this experiment, the 1696-bp pp65 gene was excised from the pUC-8-pp65 expression plasmid [Virogenetics] by NruI - BamHI digestion. The vector was blunt-ended with Klenow polymerase, digested with BamHI, and the pp65 gene inserted.

B. pARC-pp150

25 The plasmid, pARC-pp150, which expresses the pp150 tegument protein of HCMV, was constructed as follows. The pp150 gene was isolated from the HCMV genome using conventional polymerase chain reaction techniques and inserted into a suitable expression plasmid. One of skill in the art can readily isolate this gene from a desired HCMV strain making use of the published sequences in G. Jahn et al, J. Virol., 61(5):1358-1367 (1987) (which provides the nucleotide

sequences of the Ad169 HCMV pp150 gene and is incorporated by reference herein). See, also Fig. 6A-B herein [SEQ ID NO: 9 and 10].

5 In this experiment, the isolated HCMV-pp150 gene was inserted into the XbaI-restricted pARCD [Virogenetics]. The insert is approximately 3200 bp [SEQ ID NO: 10].

Example 4 - Construction of pARC-IE-Exon-4

10 The plasmid, pARC-IE-Exon-4, which expresses the HCMV-IE exon4 product [SEQ ID NO:4], was constructed as follow. The gene was obtained from pAd5-IE-Exon-4 [International Patent Application WO94/17810, published August 18, 1994 and Berencsi et al., Vaccine, 14:369-374 (1996)], by XbaI-digestion [SEQ ID NO:3]. The insert is
15 1230 bp.

Example 5 - Production of plasmid preparation stocks

E. coli DH5alpha competent cells (Gibco BRL, Gaithersburg, MD) were transformed with the constructed plasmids. Purified plasmid preparations were prepared on
20 Plasmid Giga Kits (Qiagen Inc. Chatsworth, CA).

Example 6 - Expression of HCMV-proteins after transient transfection of 293 cells with the purified plasmid preparations

25 Transient transfections were performed by the purified plasmid preparations, 1.5 μ g/ 3×10^5 cells, using lipofectamine (Gaithersburg, MD). Cells were tested for HCMV-protein expression 2 days after transfection by an immunofluorescence test as described in E. Gonczol et al, Science, 224:159-161 (1984). The antibodies used in this
30 test include the monoclonal pp65-specific Ab [VIROSTAT, Portland, Maine, stock # 0831], monoclonal gB-specific Ab [Advanced Biotechnologies, Columbia, MD], and anti-pp150

monoclonal Ab [Virogenetics Corporation]. The IE-Exon-4-specific monoclonal Ab P63-27 was provided by W. Britt, University of Alabama at Birmingham.

5 The pTet-gB plasmid expresses the full-length HCMV-gB gene under the control of a tetracycline regulatable HCMV-IE promoter. The other plasmids express the inserted gene in transfected 293 cells under the control of the HCMV-IE promoter. Expression of gB, pp65 and pp150 was found to be strong using all plasmids.

10 After transfection with pTet-gB, 10-12% and <1% of cells expressed gB protein in the absence and presence, respectively, of 1µg tetracycline [Tetracycline hydrochloride, Sigma, St. Louis, MO]. Sixty to seventy percent and 40-50% of cells transfected with pΔRC-gB and
15 pAgB₆₈₀ plasmids, respectively, expressed gB. pp65 protein was expressed in 70-80% of cells transfected with pΔRC-pp65.

Example 7 - Immunization Procedures and Assay Methods

A. Immunization procedure

20 BALB/c or CBA mice were first pretreated i.m. with 100 µl of Bupivacaine HCl [0.25% Sensorcaine-MPF (ASTRA Pharmaceutical Products, Inc. Westborough, MA)]. In some experiments, identified below, no Bupivacaine pretreatment was used. One day later DNA was inoculated
25 i.m. on the site of Bupivacaine infiltration. The dose for mice was 50-80 µg plasmid DNA/ inoculation. Booster inoculations were given i.m. 2x, without pretreatment with Bupivacaine. Mice immunized with pΔRC-gB plasmid were boosted 1 x. Mice were bled by retroorbital puncture
30 at the indicated times.

B. ELISA

Semipurified HCMV virions and purified gB proteins may be prepared by immunoaffinity column chromatography as described in E. Gonczol et al, J.

Virol., 58:661-664 (1986). Alternatively, one of skill in the art can readily obtain suitable virions and gB proteins by alternative techniques.

Semipurified HCMV virions (Towne strain) or purified gB protein preparation were used as coating antigen for detection of gB-specific antibodies. OD values higher than mean OD values \pm 2SD of preimmune sera were considered positive, or OD values >0.05 , whichever was higher. Lysates of 293 cells transiently transfected with pARC-pp65 were used as coating antigen for detection of pp65-specific antibodies, lysates prepared from untransfected 293 cells served as control antigen. OD values obtained on control antigen-coated wells were subtracted from OD values obtained on pp65 antigen-coated wells and were considered positive if the resulting value was higher than 0.05.

C. Microneutralization assay

This assay was performed as described in E. Gonczol et al., J. Virol. Methods, 14:37-41 (1986). A neutralizing titer higher than 1:8 was considered positive.

D. Cytotoxic T lymphocyte assay

This assay was performed as described in K. Berencsi et al., J. Gen Virol., 74:2507-2512 (1993). Briefly, spleen cells of immunized mice were restimulated in vitro with VacWR-pp65-infected (m.o.i. = 0.2-0.5) autologous spleen cells (effector:stimulator ratio, 2.:1) for 5 days in 24-well plates. Cytolytic activity of nonadherent spleen cells was tested in a 4-h ^{51}Cr -release assay. Target cells (P815 MHC class I-matched, MC57 MHC class I-mismatched) were infected with VacWR-pp65 or VT-Vac WR (m.o.i. = 4-8). Percentage of specific ^{51}Cr -release was calculated as [(cpm experimental release -

cpm spontaneous release)/(cpm maximal release - cpm spontaneous release) x 100]. A pp65-specific cytotoxicity higher than 10% was considered positive.

5 Example 8 - Induction of HCMV-Specific Immune Responses
by the Plasmid Constructs Expressing the gB Protein

BALB/c mice were inoculated 2 times at 0 and 5 weeks with 80 µg pARC-gB preparation. Serum samples at 5, 9 and 19 weeks after the first inoculation were tested for HCMV-specific ELISA antibodies and neutralizing
10 antibodies (NA). The results are provided in Table 1 below, in which the ELISA antigen used was semipurified virions. The OD of responders is provided as the mean±SD at a serum dilution of 1:80. Mean ± 2SD of the 6 preimmunization sera at a dilution of 1:80 gave an OD
15 value of 0.080. "GM" indicates the geometric mean.

Table 1

pARC-gB induces HCMV-specific ELISA and neutralizing antibodies (antigen: semipurified virion).

20	weeks after first inoculation	No. of ELISA responders/ total	OD of resp. dil 1:80	No. of NA resp.	GM of NA
	0	0/6	0.036±0.022	0/6	NA
25	5	5/6	0.314±0.188	2/2	19
	9	6/6	1.387±0.810	6/6	34
	19	ND	ND	4/4	22

30 These data demonstrate that all mice responded with both ELISA antibody and NA after the booster inoculation. The pARC-gB plasmid seems to be a highly potent immunizing construct.

Table 2

pTet-gB and pARC-pp65 induces insert-specific ELISA antibodies

	Mice Immunized With:	Weeks after first Inoc.	# ELISA responders /total	OD* responders
5	pTet-gB	4	1/10	0.062
		8	9/10	0.277 ± 0.257
10		13	7/7	0.530 ± 0.625
		21	6/6	0.503 ± 0.682
		31	5/6	0.451 ± 0.505
	pARC-pp65	4	5/10	0.168 ± 0.070
		8	10/10	0.568 ± 0.387
15		13	4/4	1.076 ± 0.216

* Mean OD ± SD of serum samples at dilution 1:40.

HCMV-specific ELISA antibodies were detected in 9 of 10 mice at 8 weeks after the first inoculation with pTet-gB (Table 2). HCMV neutralizing antibodies were detected in 4 of 10 mice, with titers between 1:16 and 1:48 (not shown). All mice immunized with the pARC-pp65 responded with pp65-specific ELISA antibodies. At 13 weeks (pp65- and gB-specific) and up to 31 weeks (gB-specific), OD values remained positive. In a separate experiment pp65-specific ELISA antibodies were also detected during the whole observation period (31 weeks) in 10 of the 10 immunized mice.

Example 9 - Induction of HCMV-Specific Immune Responses by the Plasmid Constructs Expressing pp65

To test whether the combination of the pTet-gB and pARC-pp65 results in reduced responses to the individual components, mice were immunized with both plasmids mixed together or inoculated separately. Groups of mice were inoculated with Bupivacaine (100 µl/mouse, 50 µl/leg),

and 2 days later, with either a mixture of both plasmids (80 μ g of each DNA/mouse, 40 μ g of each DNA/leg, 160 μ g DNA/mouse) or each plasmid inoculated into two different legs (80 μ g DNA of each plasmid/mouse, a total of 160 μ g DNA/mouse inoculated in left and right legs). A similar booster was given 4 weeks later. The time course of both the gB- and pp65-specific ELISA antibody response was very similar in both groups, with nearly all mice developing antibodies by 8 or 13 weeks after the first inoculation (Table 3). In another experiment using the combination of the two plasmids, comparable OD values were observed up to 31 weeks after the first inoculation.

Table 3

pTet-gB and p Δ RC-pp65 inoculated into the same animal induce gB and pp65-specific antibodies

Antigen, Inoculation	Weeks # gB- after ELISA 1st resp. Inoc. /Total	OD* of responders	# pp65- ELISA resp. /Total	OD of Responders
20 pTet-gB+ p Δ RC-pp65, mixed	4 4/10	0.087 \pm 0.024	5/10	0.078 \pm 0.033
	8 10/10	0.220 \pm 0.143	10/10	0.400 \pm 0.321
	13 10/10	0.392 \pm 0.152	9/10	0.303 \pm 0.224
25 pTet-gB+ p Δ RC-pp65, separately	4 8/10	0.076 \pm 0.021	6/10	0.210 \pm 0.124
	8 9/10	0.202 \pm 0.268	8/10	0.452 \pm 0.333
	13 10/10	0.309 \pm 0.202	8/10	0.308 \pm 0.212

30

* The mean OD \pm SD of serum samples at dilution 1:40.

Of six mice inoculated with p Δ RC-pp65 alone at a single site, 3 mice responded with pp65-specific lysis of target cells (Fig. 2). In a second similar experiment, 3 of 9 mice immunized with p Δ RC-pp65 alone showed strong

pp65-specific CTL responses. pp65-specific CTL were also detected in 4 of 5 tested mice inoculated with the mixture of pARC-pp65 and pTet-gB. When the pARC-pp65 and pTet-gB were inoculated separately into two different legs, 4 of 6 mice tested developed pp65-specific CTL response. These results establish that: 1) pp65-specific CTL responses are induced after DNA immunization; 2) there is no antigenic competition between the gB and pp65 proteins in the induction of antibody and CTL responses; and 3) gB protein expression in the cells at the inoculation site does not interfere with the presentation of pp65-specific T cell epitopes by MHC class I molecules to T cells.

Example 10 - Priming effect of pTet-gB

One inoculation of naked plasmid DNA in mice did not result significant antibody responses in a high percentage of mice. To find out whether the immune system of the nonresponder mice was specifically primed by the DNA inoculation, mice inoculated with pTet-gB were boosted 4 weeks later with either purified gB protein (5 μ g gB/mouse in Alum s.c.) or with the Towne strain of HCMV (20 μ g/mouse in Alum s.c.).

Table 4

Inoculation of mice with pTet-gB primes the immune system

	Antigen	wks after priming	No. of NA responder/all	GM of NA/ responder
5	Teto-gB/*	4	0/10	5
	Teto-gB	8	4/10	21
10	Teto-gB/*	4	0/10	4
	gB+Alu	8	8/10	77
	- / *	4	0/10	NA
	gB+Alu	8	1/10	16
	Teto-gB/**	12	1/5	16
	Towne+Alu	14	5/5	97
15	- / **			
	Towne+Alu	12	0/5	NA
		14	3/5	25

* second inoculations were given 4 weeks after the first inoculation
 20 ** Towne was given 12 weeks after the first inoculation

This data demonstrates that pTet-gB inoculation primes immune-responses. In other words, the combination of Teto-gB priming and gB+Alu or Towne+Alu booster gave
 25 higher number of responder mice and slightly higher NA titers than TetotTA-gB given 2 times.

Example 11 - DNA immunization decreases replication of the corresponding vaccinia recombinant in mice

Vaccinia virus recombinants expressing either HCMV-gB or pp65 were prepared using the methods described in
 30 WO 94/17810, published August 18, 1994. Briefly, the VacWR-gB and VacWR-pp65 recombinants were constructed as described [Gonczol et al, Vaccine, 9:631-637 (1991)], using the L variant of the neurovirulent WR strain of
 35 vaccinia virus as vector [Panicali et al, J. Virol.,

37(3):1000-1010 (1981)] and the gB or pp65 genes (HCMV Towne strain) as inserts cloned into the nonessential BamHI site in the HindIII F region [Panicali and Paoletti, Proc. Natl. Acad. Sci., 79:4927-4931 (1982)]
5 under the control of the vaccinia H6 early/late promoter. Vaccinia recombinant viruses and the parental wild-type WR strain were grown on Vero cells and purified as described [Gonczol et al, cited above].

After plasmid immunization, vaccinia virus
10 recombinants expressing either HCMV-gB or pp65 were used for challenge in the model described in WO 94/23744, published October 27, 1994. Vaccinia virus WR strain replicates in mouse lung after intranasal inoculation and immune protection can be evaluated by virus titrations of
15 the lung. Eight-week old female CBA and BALB/c mice were first pretreated with Bupivacaine, then 1 day later immunized either with pARC-gB or pARC-pp65 (80 µg/mouse). Mice were boosted 8 days later with DNA. Eight days after the second DNA dose mice were i.n. challenged
20 either with 5×10^6 pfu of Vaccinia WR-gB or Vaccinia WR-pp65. Lungs were taken at the time of virus challenge (day 0) and at days 1, 3, 4, 5, and 7 after challenge for virus titration. Lungs were homogenized, freeze-thaw 3
25 times and virus titer determined on Vero cells by plaque titration.

Table 5

Virus titers in the lungs of BALB/c mice immunized with pARC-gB or pARC-pp65 and challenged i.n. with Vac-gB

5	days after challenge	<u>Vac-gB titer (log±SD) in lungs*</u>		
		pARC-gB- immunized	pARC-pp65- immunized	Diff. in titer (log)
	0	3.29±2.83	3.29±2.83	0
10	1	2.24±2.9	2.76±2.51	-0.25
	3	4.86±4.61	5.60±5.45	0.53
	4	4.54±4.47	5.24±4.9	1.13
	5	4.33±3.82	5.03±4.9	1.43
	7	2.85±2.84	4.17±4.27	1.04
15	*Mean of titer (log) ± SD of 3 or 4 mice			

Table 6

Virus titers in the lungs of BALB/c mice immunized with pARC-gB or pARC-pp65 and challenged i.n. with Vac-pp65

20	days after challenge	<u>Vac - pp 65 titer (log±SD) in lungs*</u>	
		pARC-gB- immunized	pARC-pp65- immunized
25	0	5.52±4.83	5.52±4.83
	1	4.31±4.3	4.56±3.5
	3	7.68±6.75	7.15±7.11
	4	7.7±7.66	6.57±6.56
	5	7.45±6.79	6.02±6.14
30	7	7.17±6.17	6.23±6.08
	*Mean of titer (log) ± SD of 3 or 4 mice		

This data demonstrate that immunization with either plasmid reduced the titer of the corresponding challenge virus by 0.5-1.4 log on days 3, 4, 5 and 7 after the challenge.

5 Example 12 - Secreted form of gB is more potent immunogen than membrane-bound gB

10 To test whether gB bound to the membranes of gB-expressing cells or truncated form of gB lacking the transmembrane region of the molecule (it is secreted from the cell) induce stronger immune responses, mice were immunized with p Δ RC-gB (expressing membrane-bound gB) or with p Δ RCgB₆₈₀ (expressing the secreted form of gB) and ELISA and neutralizing antibody responses were evaluated as follows.

15 Plasmids p Δ RC-gB (expressing the whole gB) and Δ RC-gB₆₈₀ (expressing N-terminal 680 amino acids of the gB molecule and lacking the transmembrane region) were used in the following immunization protocol. Groups of 10 mice (BALB/c, female, 8 weeks old, purchased from HSD),
20 were inoculated i.m. in the left leg with 50 μ g plasmid DNA/mouse/inoculation. Mice were not inoculated with bupivacaine prior to DNA inoculation. Two months later a booster immunization was given (same dose, route).

25 Sera were tested in the gB-specific ELISA assay described above before the booster inoculation and 1 month after booster. The results are shown in Table 7, which shows the OD values of serum dilutions of 1:40 of individual mice. Preimmune serum samples of 40 mice were included. Cut off value: OD = 0.15.

Table 7

HCMV ELISA antibodies induced by plasmids expressing
membrane-bound or secreted form of gB

OD of sera of mice immunized with						
pΔRC-gB			pΔRC-gB ₆₈₀			
# of mouse	before booster	after booster	# of mouse	before booster	after booster	
1	0.31	0.55	1	0.83	>3.00	
2	0.09	0.10	2	0.52	>3.00	
3	0.09	0.13	3	1.65	>3.00	
4	0.06	0.08	4	0.06	0.09	
5	0.07	0.07	5	1.29	>3.00	
6	0.04	0.04	6	1.92	>3.00	
7	0.08	0.17	7	2.31	>3.00	
8	0.51	1.88	8	1.22	>3.00	
9	0.07	0.07	9	0.62	>3.00	
10	0.06	0.06	10	1.50	>3.00	

The results in Table 7 show that ten mice immunized with the pΔRC-gB₆₈₀ were positive for stronger gB-specific antibody responses than mice immunized with pΔRC-gB.

Table 8 provides the results following the immunization protocol above, where the mice had been boosted after 2 months using the same protocol as described for the first immunization. Sera obtained 1 and 2 month after the booster were tested in a HCMV-microneutralization assay. Preimmune sera were included as negative controls, NA titers ≥ 12 are considered positive.

Table 8

pΔRC-gB₆₈₀ expressing secreted form of gB induce stronger neutralizing antibody responses than pΔRC-gB expressing membrane-bound gB

NA titers of sera of mice 1 and 2 month after booster immunized with				
<u>pΔRC-gB</u>		<u>pΔRC-gB₆₈₀</u>		
	1M	2M	1M	2M
5				
10	16	24	128	64
	8	<8	64	32
	4	<4	256	192
	4	8	<4	12
	8	4	128	96
15	4	4	64	64
	8	24	64	32
	48	48	48	ND
	6	4	96	96
20	<6	4	16	24

As shown in Table 8, nine of the pΔRC-gB₆₈₀-immunized mice developed gB-specific antibodies, but only 3 of 10 responded in the pΔRC-gB-immunized group. HCMV-neutralizing antibody titers were also higher in the pΔRC-gB₆₈₀-immunized mice, 9 of 10 developed significant NA responses versus 3 of 10 in the pΔRC-gB-immunized group (Table 8).

These data show that the pΔRC-gB₆₈₀ plasmid expressing the N-terminal 680 amino acids of gB (lacking the transmembrane region of the protein) given intramuscularly induces more potent antibody responses to gB than the pΔRC-gB plasmid expressing the full gB.

Example 13 - p Δ RC-gB₆₈₀ mixed with p Δ RC-pp65 and given at one site or inoculated separately induce both gB- and pp65-specific antibodies

As shown above, pTet-gB and p Δ RC-pp65 plasmids mixed
5 and inoculated at one site induced immune responses to both gB and pp65 indicating that there is no antigenic competition between gB and pp65. In this experiment whether the p Δ RC-gB₆₈₀ (expressing the secreted form of gB) is suitable for immunization in a mixture with p Δ RC-
10 pp65 was tested.

Groups of 10 BALB/c mice (female, HSD, 9-10 weeks old) were inoculated either with a mixture of two plasmids containing 50 μ g of each in 200 μ l: 100 μ l (50 μ g) into the left leg, 100 μ l (50 μ g) into the right leg;
15 or the two different plasmids were inoculated separately: one kind of DNA (100 μ l/50 μ g) into the left leg, the other kind of plasmid (100 μ l/50 μ g) into the right leg. A booster immunization was given 1 month later. The plasmids used in this study were p Δ RC-pp65, p Δ RC-gB, and
20 p Δ RC-gB₆₈₀. Table 9 shows results obtained with sera taken 8 days after booster. The ELISA antigen was purified gB. Cut off value: 0.081.

The results show that mice immunized with mixtures of p Δ RC-gB and p Δ RC-pp65 developed both gB and pp65 ELISA
25 antibodies. Similar responses were observed in mice immunized with the two plasmids given at separate sites (Table 10 below). HCMV-gB-specific antibody responses in mice immunized with p Δ RC-gB₆₈₀ either given in mixture with p Δ RC-pp65 or at separate sites were stronger than in
30 mice immunized with the full-gB-expressing p Δ RC-gB (these results confirm that the secreted form of gB is a stronger immunogen than the membrane-bound form).

Table 9

pΔRC-gB₆₈₀ mixed with pΔRC-pp65 and given at one site
or inoculated separately induce gB-specific antibodies

gB-specific antibody (OD at serum dilutions of 1:40)								
mice inoculated with pΔRC-gB and pΔRC-pp65					mice inoculated with pΔRC-gB ₆₈₀ and pΔRC-pp65			
	mouse	at one site	mouse	at two sites	mouse	at one site	mouse	at two sites
10	#326	0.085	#356	0.115	#341	1.280	#336	1.058
	#327	0.193	#357	0.082	#342	1.070	#337	0.550
	#328	0.121	#358	0.099	#343	1.385	#338	0.193
	#329	0.060	#359	0.107	#344	1.190	#339	1.039
15	#330	0.115	#360	0.107	#345	2.588	#340	0.207
	#331	0.093	#361	NT	#351	1.037	#346	0.288
	#332	0.061	#362	0.092	#352	0.771	#347	0.220
	#333	0.089	#363	0.065	#353	0.493	#348	0.513
	#334	0.078	#364	0.152	#354	0.560	#349	0.223
20	#335	0.088	#365	0.082	#355	0.933	#350	0.719
	Mean	0.098		0.100		1.130		0.521
	OD:							

Mice immunized as above with the mixture of pΔRC-gB₆₈₀ and pΔRC-pp65 showed gB-specific antibody responses similar to those observed in mice immunized with the two kinds of plasmids given at separate sites. Results of pp65-specific antibody responses showed that mice responded to the pp65 antigen regardless of immunization with a mixture or with plasmids given at separate sites (Table 10). Table 10 shows results obtained with sera taken 8 days after booster (cut off value: 0.050).

Table 10

pΔRC-gB₆₈₀ mixed with pΔRC-pp65 and given at one site
or inoculated separately induce pp65-specific antibodies

5 pp65-specific antibody (OD at serum dilutions of 1:40)

mice inoculated with pΔRC-gB and pΔRC-pp65 pp65					mice inoculated with pΔRC-gB ₆₈₀ and pΔRC- pp65			
10	<u>mouse</u>	<u>at one site</u>	<u>mouse</u>	<u>at two sites</u>	<u>mouse</u>	<u>at one site</u>	<u>mouse</u>	<u>at two sites</u>
	#326	0.037	#356	0.000	#341	0.389	#336	0.276
	#327	0.149	#357	0.000	#342	0.238	#337	0.295
	#328	0.002	#358	0.508	#343	0.440	#338	0.000
15	#329	0.000	#359	0.008	#344	0.077	#339	0.009
	#330	0.009	#360	0.176	#345	0.008	#340	0.030
	#331	0.007	#361	dead	#351	0.081	#346	0.051
	#332	0.014	#362	0.009	#352	0.077	#347	0.124
	#333	0.000	#363	0.028	#353	0.049	#348	0.281
20	#334	0.000	#364	0.097	#354	0.016	#349	0.118
	#335	0.008	#365	0.201	#355	0.178	#350	0.014
	Mean	0.014		0.109		0.154		0.111
	OD:							

25 The data show that mice develop significant immune
responses both to gB and pp65 after immunization with a
mixture of pΔRC-gB₆₈₀ and pΔRC-pp65, indicating that
these two HCMV antigens are able to induce parallel
immune responses when introduced by expression plasmids
30 to the immune system.

Example 14 - Immunization Studies in Mice Immunized with HCMV Plasmid Vectors Expressing Full-Length and Transmembrane-Deleted gB

As shown in the studies described above, full-length gB and transmembrane-deleted gB have been found to induce a strong and long-term antibody response when delivered by plasmid DNA. The following experiments provide further evidence of this effect.

A. pCBgB and pCBgB Δ tm

The gB open reading frame (ORF, nucleotides 1-2724) was obtained from the CMV Towne strain [SEQ ID NO: 1] using conventional techniques. The gB Δ tm (transmembrane-deleted gB) was obtained from the wild type gene by deleting in frame the sequences coding for the hydrophobic transmembrane domain of the protein [nucleotides 2143 - 2316 were deleted from the gB ORF, SEQ ID NO:1]. These two coding sequences were introduced into the polylinker of the eukaryotic expression vector pCB11 corresponding to a commercially available pUC backbone with the HCMV IE1 promoter/enhancer sequences and the terminator sequences from the bovine growth hormone gene (Fig. 7A). The resulting plasmids, pCBgB and pCBgB Δ tm expressing the full-length gB and its truncated version, respectively, are shown in Fig. 8. Protein expression from pCBgB and from pCBgB Δ tm was confirmed by immunofluorescence and immunoprecipitation after transfection into cultured CHO-K1 cells. The immunoprecipitation experiment indicated that only pCBgB Δ tm gave rise to a secreted form of gB which could be recovered from the cell culture medium.

B. Immunization

The study described below was performed with pCBgB and pCBgB Δ tm in 6-8 week old female BALB/c mice. Anesthetized (xylazine + ketamine) mice (8 per group) received three administrations of 50 μ g pCBgB or pCBgB Δ tm

at three week intervals (days 0, 21 and 42) either intramuscularly (IM) or intradermally (ID). For IM administration, DNA in 50 μ l of saline was injected into the quadriceps with a Hamilton syringe equipped with a 20 gauge needle. For ID administration, DNA in a total volume of 100 μ l of saline was injected into 5 sites of shaved dorsal skin with a pneumatic jet injector.

In each group, mice were labeled and bled on days 14 (following 1 injection), 35 (following 2 injections), 56 (following 3 injections), 116 and 202. The anti-urease IgG antibody response was followed by ELISA against recombinant gB produced in MRC5 cells infected with ALVAC-gB. The sera collected on days 116 and 202 were analyzed for hCMV neutralization in complement dependent microneutralization assay [Gonczol et al, cited above (1986)]. The data is provided in Table 11 and summarized in Fig. 9.

TABLE 11

INDIVIDUAL ELISA TITERS
IN MICE IMMUNIZED WITH HCMV GB PLASMID VECTORS

Day	# Mouse	Intramuscular		Intradermal		neg. serum
		pCBgB ELISA	pCBgB Δ tm ELISA	pCBgB ELISA	pCBgB Δ tm ELISA	
25	14	1	50	50	<50	<50
		2	<50	200	<50	<50
		3	100	9600	100	<50
		4	<50	300	<50	<50
		5	100	100	<50	<50
		6	<50	75	<50	50
30		7	100	75	<50	<50
		8	50	<50	<50	<50
35	35	1	100	100	75	50
		2	150	900	150	600
		3	200	12800	6400	2400
		4	150	3200	1600	200
		5	400	1200	100	1600
		6	100	1200	1200	6400
40		7	150	300	75	100
		8	150	100	200	150

TABLE 11 (con't)

INDIVIDUAL ELISA TITERS
IN MICE IMMUNIZED WITH HCMV GB PLASMID VECTORS

5	Day	# Mouse	Intramuscular		Intradermal		neg. serum
			pCBgB ELISA	pCBgB Δ tm ELISA	pCBgB ELISA	pCBgB Δ tm ELISA	
10	56	1	150	1600	200	1200	<50
		2	200	2400	200	38400	<50
		3	200	38400	6400	12800	
		4	75	61200	6400	12800	
		5	400	2400	1200	4800	
		6	100	38400	3200	9600	
		7	200	19200	600	1600	
		8	600	4800	1200	4800	
20	116	1	<50	1200	75	600	<50
		2	1600	800	37.5	12800	<50
		3	400	9600	1200	640	
		4	<50	25600	2400	4800	
		5	25	1600	150	800	
		6	<50	25600	1600	4800	
		7	<50	6400	300	800	
		8	200	1200	200	800	
25	202	1	<50	1000	50	250	<50
		2	400	1000	25	8000	<50
		3	1600	8000	800	3000	
		4	<50	64000	1600	1500	
		5	25	1500	50	500	
30		6	<50	24000	1200	3000	
		7	<50	4000	200	375	
		8		1000	150	375	

As illustrated in Table 11 above and in Fig. 9,
pCBgB and pCBgB Δ tm plasmids induced serum IgGs against
recombinant gB protein after IM or ID administration in
BALB/c mice [pCBgB Δ tm/ID \geq pCBgB Δ tm/IM \gg pCBgB/ID \geq
pCBgB/IM]. pCBgB and pCBgB Δ tm plasmids induced
detectable neutralizing antibodies to HCMV (in vitro
assay) after IM or ID administration in BALB/c mice
[pCBgB Δ tm > pCBgB].

pCB-gB and pCB-gB Δ tm have been observed to induce a strong and long-term antibody response. pCBgB and especially pCB-gB Δ tm induce neutralizing antibodies.

5 The nature of the response (IgG₁/IgG_{2a}) differs between pCB-gB and pCB-gB Δ tm. Particularly, pCB-gB has been observed to induce an IgG₁ (T_{H2}) response which is approximately equivalent to the IgG_{2a} (T_{H1}) response induced. In contrast, pCB-gB Δ tm has been observed to induce an IgG₁ response that is significantly stronger
10 that the IgG_{2a} response induced.

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to
15 the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

International Application No: PCT/

/

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 8, lines 9-10 of the description ***A. IDENTIFICATION OF DEPOSIT ***

pTet-gB

Further deposits are identified on an additional sheet ☐ *

Name of depository institution *

American Type Culture Collection

Address of depository institution (including postal code and country) *

12301 Parklawn Drive
Rockville, Maryland 20852 USA

Date of deposit *

April 23, 1996

Accession Number *

98029

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS *** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)PAUL F. URRUTIA *PFU*

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau *

was

(Authorized Officer)

WHAT IS CLAIMED IS:

1. A DNA molecule which is non-replicating in mammals and comprises a sequence encoding a human cytomegalovirus antigen,
wherein the sequence is operably linked to regulatory sequences for expressing the antigen in mammals and wherein the antigen elicits an immune response in the mammal.
2. The DNA molecule according to claim 1 which is a plasmid.
3. The DNA molecule according to claim 1 or claim 2 wherein said antigen is selected from the group consisting of:
 - (a) gB;
 - (b) a gB derivative lacking at least the transmembrane domain;
 - (c) pp65;
 - (d) pp150;
 - (e) immediate-early exon-4; and
 - (f) combinations of (a) - (e).
4. The DNA molecule according to claim 3 which comprises a sequence encoding the gB and the pp65 antigens.
5. The DNA molecule according to claim 3 which comprises a sequence encoding the gB derivative and a sequence encoding the pp65 antigen.

6. A pTet-gB DNA plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gB gene and a tetracycline regulatable HCMV-immediate early promoter, said promoter controlling the expression of gB.

7. A p Δ ARC/CMV DNA plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gB gene and capable of expressing gB.

8. A p Δ ARC-gB₆₈₀ plasmid, said plasmid comprising the portion of the human cytomegalovirus (HCMV) gene encoding the N-terminal 680 amino acids of the gB protein (gB₁₋₆₈₀) and capable of expressing gB₁₋₆₈₀.

9. A p Δ ARC-pp65 plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gene encoding the HCMV pp65 tegument protein and capable of expressing pp65.

10. A p Δ ARC-pp150 plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gene encoding the HCMV pp150 tegument protein and capable of expressing pp150.

11. A p Δ ARC-exon-4 plasmid, said plasmid comprising the portion of the human cytomegalovirus (HCMV) gene encoding HCMV immediate-early (IE)-exon-4 and capable of expressing IE-exon-4.

12. An immunogenic composition comprising a carrier and a DNA molecule according to any of claims 1-5.

13. The immunogenic composition according to claim 12 wherein the DNA molecule is selected from the group consisting of:

- (a) pΔRC-gB;
- (b) pTet-gB;
- (c) pΔRC-pp65;
- (d) pΔRC-gB₆₈₀;
- (e) pΔRC-pp150; and
- (f) pΔRC-exon-4.

14. The immunogenic composition according to claim 12 or 13 comprising two or more DNA molecules.

15. The immunogenic composition according to claim 14 comprising a first DNA molecule which comprises a sequence encoding the gB antigen or a gB derivative, and a second DNA molecule which comprises a sequence encoding the pp65 antigen.

16. The immunogenic composition according to any of claims 12 to 15 wherein the carrier is selected from the group consisting of saline and isotonic water.

17. A method of inducing human cytomegalovirus-specific (HCMV) immune responses in an animal, comprising the step of administering to said animal an effective amount of a first immunogenic composition according to any of claims 12 to 16.

18. The method according to claim 17 wherein the composition comprises pTet-gB and pΔRC-pp65.

19. The method according to claim 16 further comprising the step of administering a second immunogenic composition to said animal, said second immunogenic composition comprising a plasmid selected from the group consisting of:

- (a) p Δ RC-gB;
- (b) pTet-gB;
- (c) p Δ RC-pp65;
- (d) p Δ RC-gB₆₈₀;
- (e) p Δ RC-pp150; and
- (f) p Δ RC-IE-Exon-4.

20. The method according to claim 17, wherein said second immunogenic composition is administered between about 2 to about 15 weeks following administration of said first immunogenic composition.

21. The use of a DNA molecule according to any of claims 1 to 5 or a plasmid according to any of claims 6 to 11 in the preparation of a medicament to treat a cytomegalovirus infection.

22. A method of priming immune responses to a selected human cytomegalovirus immunogenic composition, comprising the steps of:

administering a first immunogenic composition according to any of claims 12 to 16 and administering the selected human cytomegalovirus immunogenic composition.

23. The method according to claim 22 wherein the first immunogenic composition is administered between about 4 and 15 weeks prior to administration of the selected immunogenic composition.

24. The method according to claim 22 or claim 23 wherein the first immunogenic composition comprises pTet-gB.

25. The method according to claim 24, wherein pTet-gB is administered in an amount between about 50 μ g to about 160 μ g.

26. The method according to claim 22, wherein the selected immunogenic composition comprises an immunogen selected from the group consisting of a recombinant virus comprising an HCMV immunogen, an HCMV protein, and HCMV virions.

27. The method according to claim 26 wherein the HCMV protein is gB.

28. The method according to claim 26 wherein the recombinant virus is selected from the group consisting of Ad5.gb and Ad5-IE-exon-4.

AMENDED CLAIMS

[received by the International Bureau on 25 November 1997 (25.11.97);
original claims 13-28 replaced by new claims 13-32; remaining claims unchanged (4 pages)]

13. A pCBgB Δ tm plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gB gene containing a deletion in the transmembrane domain.

14. An immunogenic composition comprising a carrier and a DNA molecule according to any of claims 1-5.

15. The immunogenic composition according to claim 14 wherein the DNA molecule is selected from the group consisting of:

- (a) p Δ RC-gB;
- (b) pTet-gB;
- (c) p Δ RC-pp65;
- (d) p Δ RC-gB₆₈₀;
- (e) p Δ RC-pp150;
- (f) pCBgB;
- (g) pCBgB Δ tm; and
- (h) p Δ RC-exon-4.

16. The immunogenic composition according to claim 14 or 15 comprising two or more DNA molecules.

17. The immunogenic composition according to claim 15 comprising a first DNA molecule which comprises a sequence encoding the gB antigen or a gB derivative, and a second DNA molecule which comprises a sequence encoding the pp65 antigen.

18. The immunogenic composition according to any of claims 13 to 17 wherein the carrier is selected from the group consisting of saline and isotonic water.

19. A method of inducing human cytomegalovirus-specific (HCMV) immune responses in an animal, comprising the step of administering to said animal an effective amount of a first immunogenic composition according to any of claims 14 to 18.

20. The method according to claim 19 wherein the composition comprises pTet-gB and pΔRC-pp65.

21. The method according to claim 19 further comprising the step of administering a second immunogenic composition to said animal, said second immunogenic composition comprising a plasmid selected from the group consisting of:

- (a) pΔRC-gB;
- (b) pTet-gB;
- (c) pΔRC-pp65;
- (d) pΔRC-gB₆₈₀;
- (e) pΔRC-pp150;
- (f) pCBgB;
- (g) pCBgBΔtm; and
- (h) pΔRC-IE-Exon-4.

22. The method according to claim 19, wherein said second immunogenic composition is administered between about 2 to about 15 weeks following administration of said first immunogenic composition.

23. The use of a DNA molecule according to any of claims 1 to 5 or a plasmid according to any of claims 6 to 13 in the preparation of a medicament to treat a cytomegalovirus infection.

24. A method of priming immune responses to a selected human cytomegalovirus immunogenic composition, comprising the steps of:
administering a first immunogenic composition according to any of claims 14 to 18 and administering the selected human cytomegalovirus immunogenic composition.

25. The method according to claim 24 wherein the first immunogenic composition is administered between about 4 and 15 weeks prior to administration of the selected immunogenic composition.

26. The method according to claim 24 or claim 25 wherein the first immunogenic composition comprises pTet-gB.

27. The method according to claim 26, wherein pTet-gB is administered in an amount between about 50 μ g to about 160 μ g.

28. The method according to claim 24, wherein the selected immunogenic composition comprises an immunogen selected from the group consisting of a recombinant virus comprising an HCMV immunogen, an HCMV protein, and HCMV virions.

29. The method according to claim 28 wherein the HCMV protein is gB.

30. The method according to claim 28 wherein the recombinant virus is selected from the group consisting of Ad5.gb and Ad5-IE-exon-4.

31. A DNA molecule which is non-replicating in mammals and comprises a sequence encoding a human cytomegalovirus antigen selected from the group consisting of:

- (a) pp65;
- (b) pp150;
- (c) immediate-early exon-4;
- (d) gB and an antigen of (a) to (c);
- (e) a gB derivative lacking at least the transmembrane domain and an antigen of (a) to (c); and
- (f) a combination of antigens (a) to (c).

32. An immunogenic composition comprising a carrier and at least two DNA molecules, wherein said DNA molecules are selected from the group consisting of:

- (a) gB;
- (b) a gB derivative lacking at least the transmembrane domain;
- (c) pp65;
- (d) pp150; and
- (e) immediate-early exon-4.

STATEMENT UNDER ARTICLE 19

Following entry of the attached replacement pages, claims 1 - 32 are pending.

The claims have been amended to recite two plasmid constructs disclosed throughout the application, but not previously claimed. See, new claims 12 and 13, amended claims 15 and 21. Particularly, pCBgB and pCBgB Δ tm are supported in Example 14, page 34, line 1 through page 37, line 10 of the specification as filed. No new matter is added by this amendment. Inclusion of these two claims requires addition of two additional inventors, as requested in the attached letter.

In addition, two new independent claims have been added, which are supported by original claims 1 and 12, but are of narrower scope. These claims are believed to overcome the prior art cited in the International Search Report.




FIG. 1

SUBSTITUTE SHEET (RULE 28)

2/27




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/27

FIGURE 3A

ATG	GAA	TCC	AGG	ATC	TGG	TGC	CTG	GTA	GTC	TGC	GTT	AAC	TTG	TGT	45
Met	Glu	Ser	Arg	Ile	Trp	Cys	Leu	Val	Val	Cys	Val	Asn	Leu	Cys	15
1				5					10						
ATC	GTC	TGT	CTG	GGT	GCT	GCG	GTT	TCC	TCA	TCT	TCT	ACT	CGT	GGA	90
Ile	Val	Cys	Leu	Gly	Ala	Ala	Val	Ser	Ser	Ser	Ser	Thr	Arg	Gly	30
				20					25						
ACT	TCT	GCT	ACT	CAC	AGT	CAC	CAT	TCC	TCT	CAT	ACG	ACG	TCT	GCT	135
Thr	Ser	Ala	Thr	His	Ser	His	His	Ser	Ser	His	Thr	Thr	Ser	Ala	45
				35					40						
GCT	CAT	TCT	CGA	TCC	GGT	TCA	GTC	TCT	CAA	CGC	GTA	ACT	TCT	TCC	180
Ala	His	Ser	Arg	Ser	Gly	Ser	Val	Ser	Gln	Arg	Val	Thr	Ser	Ser	60
				50					55						
CAA	ACG	GTC	AGC	CAT	GGT	GTT	AAC	GAG	ACC	ATC	TAC	AAC	ACT	ACC	225
Gln	Thr	Val	Ser	His	Gly	Val	Asn	Glu	Thr	Ile	Tyr	Asn	Thr	Thr	75
				65					70						
CTC	AAG	TAC	GGA	GAT	GTG	GTG	GGG	GTC	AAC	ACC	ACC	AAG	TAC	CCC	270
Leu	Lys	Tyr	Gly	Asp	Val	Val	Gly	Val	Asn	Thr	Thr	Lys	Tyr	Pro	90
				80					85						
TAT	CGC	GTG	TGT	TCT	ATG	GCA	CAG	GGT	ACG	GAT	CTT	ATT	CGC	TTT	315
Tyr	Arg	Val	Cys	Ser	Met	Ala	Gln	Gly	Thr	Asp	Leu	Ile	Arg	Phe	105
				95					100						
GAA	CGT	AAT	ATC	GTC	TGC	ACC	TCG	ATG	AAG	CCC	ATC	AAT	GAA	GAC	360
Glu	Arg	Asn	Ile	Val	Cys	Thr	Ser	Met	Lys	Pro	Ile	Asn	Glu	Asp	120
				110					115						
CTG	GAC	GAG	GGC	ATC	ATG	GTG	GTC	TAC	AAA	CGC	AAC	ATC	GTC	GCG	405
Leu	Asp	Glu	Gly	Ile	Met	Val	Val	Tyr	Lys	Arg	Asn	Ile	Val	Ala	135
				125					130						
CAC	ACC	TTT	AAG	GTA	CGA	GTC	TAC	CAG	AAG	GTT	TTG	ACG	TTT	CGT	450
His	Thr	Phe	Lys	Val	Arg	Val	Tyr	Gln	Lys	Val	Leu	Thr	Phe	Arg	150
				140					145						
CGT	AGC	TAC	GCT	TAC	ATC	CAC	ACC	ACT	TAT	CTG	CTG	GGC	AGC	AAC	495
Arg	Ser	Tyr	Ala	Tyr	Ile	His	Thr	Thr	Tyr	Leu	Leu	Gly	Ser	Asn	165
				155					160						
ACG	GAA	TAC	GTG	GCG	CCT	CCT	ATG	TGG	GAG	ATT	CAT	CAT	ATC	AAC	540
Thr	Glu	Tyr	Val	Ala	Pro	Pro	Met	Trp	Glu	Ile	His	His	Ile	Asn	180
				170					175						
AGT	CAC	AGT	CAG	TGC	TAC	AGT	TCC	TAC	AGC	CGC	GTT	ATA	GCA	GGC	585
Ser	His	Ser	Gln	Cys	Tyr	Ser	Ser	Tyr	Ser	Arg	Val	Ile	Ala	Gly	195
				185					190						
ACG	GTT	TTC	GTG	GCT	TAT	CAT	AGG	GAC	AGC	TAT	GAA	AAC	AAA	ACC	630
Thr	Val	Phe	Val	Ala	Tyr	His	Arg	Asp	Ser	Tyr	Glu	Asn	Lys	Thr	210
				200					205						

SUBSTITUTE SHEET (RULE 28)

4/27

FIGURE 3B

ATG	CAA	TTA	ATG	CCC	GAC	GAT	TAT	TCC	AAC	ACC	CAC	AGT	ACC	CGT	675
Met	Gln	Leu	Met	Pro	Asp	Asp	Tyr	Ser	Asn	Thr	His	Ser	Thr	Arg	
				215					220					225	
TAC	GTG	ACG	GTC	AAG	GAT	CAA	TGG	CAC	AGC	CGC	GGC	AGC	ACC	TGG	720
Tyr	Val	Thr	Val	Lys	Asp	Gln	Trp	His	Ser	Arg	Gly	Ser	Thr	Trp	
				230					235					240	
CTC	TAT	CGT	GAG	ACC	TGT	AAT	CTG	AAT	TGT	ATG	GTG	ACC	ATC	ACT	765
Leu	Tyr	Arg	Glu	Thr	Cys	Asn	Leu	Asn	Cys	Met	Val	Thr	Ile	Thr	
				245					250					255	
ACT	GCG	CGC	TCC	AAG	TAT	CCC	TAT	CAT	TTT	TTC	GCA	ACT	TCC	ACG	810
Thr	Ala	Arg	Ser	Lys	Tyr	Pro	Tyr	His	Phe	Phe	Ala	Thr	Ser	Thr	
				260					265					270	
GGT	GAT	GTG	GTT	GAC	ATT	TCT	CCT	TTC	TAC	AAC	GGA	ACT	AAT	CGC	855
Gly	Asp	Val	Val	Asp	Ile	Ser	Pro	Phe	Tyr	Asn	Gly	Thr	Asn	Arg	
				275					280					285	
AAT	GCC	AGC	TAT	TTT	GGA	GAA	AAC	GCC	GAC	AAG	TTT	TTC	ATT	TTT	900
Asn	Ala	Ser	Tyr	Phe	Gly	Glu	Asn	Ala	Asp	Lys	Phe	Phe	Ile	Phe	
				290					295					300	
CCG	AAC	TAC	ACT	ATC	GTC	TCC	GAC	TTT	GGA	AGA	CCG	AAT	TCT	GCG	945
Pro	Asn	Tyr	Thr	Ile	Val	Ser	Asp	Phe	Gly	Arg	Pro	Asn	Ser	Ala	
				305					310					315	
TTA	GAG	ACC	CAC	AGG	TTG	GTG	GCT	TTT	CTT	GAA	CGT	GCG	GAC	TCA	990
Leu	Glu	Thr	His	Arg	Leu	Val	Ala	Phe	Leu	Glu	Arg	Ala	Asp	Ser	
				320					325					330	
GTG	ATC	TCC	TGG	GAT	ATA	CAG	GAC	GAG	AAG	AAT	GTT	ACT	TGT	CAA	1035
Val	Ile	Ser	Trp	Asp	Ile	Gln	Asp	Glu	Lys	Asn	Val	Thr	Cys	Gln	
				335					340					345	
CTC	ACT	TTC	TGG	GAA	GCC	TCG	GAA	CGC	ACC	ATT	CGT	TCC	GAA	GCC	1080
Leu	Thr	Phe	Trp	Glu	Ala	Ser	Glu	Arg	Thr	Ile	Arg	Ser	Glu	Ala	
				350					355					360	
GAG	GAC	TCG	TAT	CAC	TTT	TCT	TCT	GCC	AAA	ATG	ACC	GCC	ACT	TTC	1125
Glu	Asp	Ser	Tyr	His	Phe	Ser	Ser	Ala	Lys	Met	Thr	Ala	Thr	Phe	
				365					370					375	
TTA	TCT	AAG	AAG	CAA	GAG	GTG	AAC	ATG	TCC	GAC	TCT	GCG	CTG	GAC	1170
Leu	Ser	Lys	Lys	Gln	Glu	Val	Asn	Met	Ser	Asp	Ser	Ala	Leu	Asp	
				380					385					390	
TGT	GTA	CGT	GAT	GAG	GCC	ATA	AAT	AAG	TTA	CAG	CAG	ATT	TTC	AAT	1215
Cys	Val	Arg	Asp	Glu	Ala	Ile	Asn	Lys	Leu	Gln	Gln	Ile	Phe	Asn	
				395					400					405	
ACT	TCA	TAC	AAT	CAA	ACA	TAT	GAA	AAA	TAT	GGA	AAC	GTG	TCC	GTC	1260
Thr	Ser	Tyr	Asn	Gln	Thr	Tyr	Glu	Lys	Tyr	Gly	Asn	Val	Ser	Val	
				410					415					420	

SUBSTITUTE SHEET (RULE 28)

5/27

FIGURE 3C

TTT	GAA	ACC	ACT	GGT	GGT	TTG	GTG	GTG	TTC	TGG	CAA	GGT	ATC	AAG	1305
Phe	Glu	Thr	Thr	Gly	Gly	Leu	Val	Val	Phe	Trp	Gln	Gly	Ile	Lys	435
				425					430						
CAA	AAA	TCT	CTG	GTG	GAA	CTC	GAA	CGT	TTG	GCC	AAC	CGC	TCC	AGT	1350
Gln	Lys	Ser	Leu	Val	Glu	Leu	Glu	Arg	Leu	Ala	Asn	Arg	Ser	Ser	450
				440					445						
CTG	AAT	CTT	ACT	CAT	AAT	AGA	ACC	AAA	AGA	AGT	ACA	GAT	GGC	AAC	1395
Leu	Asn	Leu	Thr	His	Asn	Arg	Thr	Lys	Arg	Ser	Thr	Asp	Gly	Asn	465
				455					460						
AAT	GCA	ACT	CAT	TTA	TCC	AAC	ATG	GAG	TCG	GTG	CAC	AAT	CTG	GTC	1440
Asn	Ala	Thr	His	Leu	Ser	Asn	Met	Glu	Ser	Val	His	Asn	Leu	Val	480
				470					475						
TAC	GCC	CAG	CTG	CAG	TTC	ACC	TAT	GAC	ACG	TTG	CGC	GGT	TAC	ATC	1485
Tyr	Ala	Gln	Leu	Gln	Phe	Thr	Tyr	Asp	Thr	Leu	Arg	Gly	Tyr	Ile	495
				485					490						
AAC	CGG	GCG	CTG	GCG	CAA	ATC	GCA	GAA	GCC	TGG	TGT	GTG	GAT	CAA	1530
Asn	Arg	Ala	Leu	Ala	Gln	Ile	Ala	Glu	Ala	Trp	Cys	Val	Asp	Gln	510
				500					505						
CGG	CGC	ACC	CTA	GAG	GTC	TTC	AAG	GAA	CTT	AGC	AAG	ATC	AAC	CCG	1575
Arg	Arg	Thr	Leu	Glu	Val	Phe	Lys	Glu	Leu	Ser	Lys	Ile	Asn	Pro	525
				515					520						
TCA	GCT	ATT	CTC	TCG	GCC	ATC	TAC	AAC	AAA	CCG	ATT	GCC	GCG	CGT	1620
Ser	Ala	Ile	Leu	Ser	Ala	Ile	Tyr	Asn	Lys	Pro	Ile	Ala	Ala	Arg	540
				530					535						
TTC	ATG	GGT	GAT	GTC	CTG	GGT	CTG	GCC	AGC	TGC	GTG	ACC	ATT	AAC	1665
Phe	Met	Gly	Asp	Val	Leu	Gly	Leu	Ala	Ser	Cys	Val	Thr	Ile	Asn	555
				545					550						
CAA	ACC	AGC	GTC	AAG	GTG	CTG	CGT	GAT	ATG	AAT	GTG	AAG	GAA	TCG	1710
Gln	Thr	Ser	Val	Lys	Val	Leu	Arg	Asp	Met	Asn	Val	Lys	Glu	Ser	570
				560					565						
CCA	GGA	CGC	TGC	TAC	TCA	CGA	CCA	GTG	GTC	ATC	TTT	AAT	TTC	GCC	1755
Pro	Gly	Arg	Cys	Tyr	Ser	Arg	Pro	Val	Val	Ile	Phe	Asn	Phe	Ala	585
				575					580						
AAC	AGC	TCG	TAC	GTG	CAG	TAC	GGT	CAA	CTG	GGC	GAG	GAT	AAC	GAA	1800
Asn	Ser	Ser	Tyr	Val	Gln	Tyr	Gly	Gln	Leu	Gly	Glu	Asp	Asn	Glu	600
				590					595						
ATC	CTG	TTG	GGC	AAC	CAC	CGC	ACT	GAG	GAA	TGT	CAG	CTT	CCC	AGC	1845
Ile	Leu	Leu	Gly	Asn	His	Arg	Thr	Glu	Glu	Cys	Gln	Leu	Pro	Ser	615
				605					610						
CTC	AAG	ATC	TTC	ATC	GCC	GGC	AAC	TCG	GCC	TAC	GAG	TAC	GTG	GAC	1890
Leu	Lys	Ile	Phe	Ile	Ala	Gly	Asn	Ser	Ala	Tyr	Glu	Tyr	Val	Asp	630
				620					625						

SUBSTITUTE SHEET (RULE 20)

6/27

FIGURE 3D

TAC	CTC	TTC	AAA	CGC	ATG	ATT	GAC	CTC	AGC	AGC	ATC	TCC	ACC	GTC	1935
Tyr	Leu	Phe	Lys	Arg	Met	Ile	Asp	Leu	Ser	Ser	Ile	Ser	Thr	Val	
				635					640					645	
GAC	AGC	ATG	ATC	GCC	CTA	GAC	ATC	GAC	CCG	CTG	GAA	AAC	ACC	GAC	1980
Asp	Ser	Met	Ile	Ala	Leu	Asp	Ile	Asp	Pro	Leu	Glu	Asn	Thr	Asp	
				650					655					660	
TTC	AGG	GTA	CTG	GAA	CTT	TAC	TCG	CAG	AAA	GAA	TTG	CGT	TCC	AGC	2025
Phe	Arg	Val	Leu	Glu	Leu	Tyr	Ser	Gln	Lys	Glu	Leu	Arg	Ser	Ser	
				665					670					675	
AAC	GTT	TTT	GAT	CTC	GAG	GAG	ATC	ATG	CGC	GAG	TTC	AAT	TCG	TAT	2070
Asn	Val	Phe	Asp	Leu	Glu	Glu	Ile	Met	Arg	Glu	Phe	Asn	Ser	Tyr	
				680					685					690	
AAG	CAG	CGG	GTA	AAG	TAC	GTG	GAG	GAC	AAG	GTA	GTC	GAC	CCG	CTG	2115
Lys	Gln	Arg	Val	Lys	Tyr	Val	Glu	Asp	Lys	Val	Val	Asp	Pro	Leu	
				695					700					705	
CCG	CCC	TAC	CTC	AAG	GGT	CTG	GAC	GAC	CTC	ATG	AGC	GGC	CTG	GGC	2160
Pro	Pro	Tyr	Leu	Lys	Gly	Leu	Asp	Asp	Leu	Met	Ser	Gly	Leu	Gly	
				710					715					720	
GCC	GCG	GGA	AAG	GCC	GTT	GGC	GTA	GCC	ATT	GGG	GCC	GTG	GGT	GGC	2205
Ala	Ala	Gly	Lys	Ala	Val	Gly	Val	Ala	Ile	Gly	Ala	Val	Gly	Gly	
				725					730					735	
GCG	GTG	GCC	TCC	GTG	GTC	GAA	GGC	GTT	GCC	ACC	TTC	CTC	AAA	AAC	2250
Ala	Val	Ala	Ser	Val	Val	Glu	Gly	Val	Ala	Thr	Phe	Leu	Lys	Asn	
				740					745					750	
CCC	TTC	GGA	GCC	TTC	ACC	ATC	ATC	CTC	GTG	GCC	ATA	GCC	GTC	GTC	2295
Pro	Phe	Gly	Ala	Phe	Thr	Ile	Ile	Leu	Val	Ala	Ile	Ala	Val	Val	
				755					760					765	
ATT	ATC	ATT	TAT	TTG	ATC	TAT	ACT	CGA	CAG	CGG	CGT	CTC	TGC	ATG	2340
Tyr	Leu	Ile	Tyr	Thr	Arg	Gln	Arg	Arg	Leu	Cys	Met	Gln	Pro	Leu	
				770					775					780	
CAG	CCG	CTG	CAG	AAC	CTC	TTT	CCC	TAT	CTG	GTG	TCC	GCC	GAC	GGG	2385
Ile	Ile	Ile	Gln	Asn	Leu	Phe	Pro	Tyr	Leu	Val	Ser	Ala	Asp	Gly	
				785					790					795	
ACC	ACC	GTG	ACG	TCG	GGC	AAC	ACC	AAA	GAC	ACG	TCG	TTA	CAG	GCT	2430
Thr	Thr	Val	Thr	Ser	Gly	Asn	Thr	Lys	Asp	Thr	Ser	Leu	Gln	Ala	
				800					805					810	
CCG	CCT	TCC	TAC	GAG	GAA	AGT	GTT	TAT	AAT	TCT	GGT	CGC	AAA	GGA	2475
Pro	Pro	Ser	Tyr	Glu	Glu	Ser	Val	Tyr	Asn	Ser	Gly	Arg	Lys	Gly	
				815					820					825	
CCG	GGA	CCA	CCG	TCG	TCT	GAT	GCA	TCC	ACG	GCG	GCT	CCG	CCT	TAC	2520
Pro	Gly	Pro	Pro	Ser	Ser	Asp	Ala	Ser	Thr	Ala	Ala	Pro	Pro	Tyr	
				830					835					840	

SUBSTITUTE SHEET (RULE 26)

7/27

FIGURE 3E

ACC	AAC	GAG	CAG	GCT	TAC	CAG	ATG	CTT	CTG	GCC	CTG	GTC	CGT	CTG	2565
Thr	Asn	Glu	Gln	Ala	Tyr	Gln	Met	Leu	Leu	Ala	Leu	Val	Arg	Leu	
				845					850					855	
GAC	GCA	GAG	CAG	CGA	GCG	CAG	CAG	AAC	GGT	ACA	GAT	TCT	TTG	GAC	2610
Asp	Ala	Glu	Gln	Arg	Ala	Gln	Gln	Asn	Gly	Thr	Asp	Ser	Leu	Asp	
				860					865					870	
GGA	CAG	ACT	GGC	ACG	CAG	GAC	AAG	GGA	CAG	AAG	CCC	AAC	CTG	CTA	2655
Gly	Gln	Thr	Gly	Thr	Gln	Asp	Lys	Gly	Gln	Lys	Pro	Asn	Leu	Leu	
				875					880					885	
GAC	CGA	CTG	CGA	CAC	CGC	AAA	AAC	GGC	TAC	CGA	CAC	TTG	AAA	GAC	2700
Asp	Arg	Leu	Arg	His	Arg	Lys	Asn	Gly	Tyr	Arg	His	Leu	Lys	Asp	
				890					895					900	
TCC	GAC	GAA	GAA	GAG	AAC	GTC	TGA								2724
Ser	Asp	Glu	Glu	Glu	Asn	Val									
				905											

SUBSTITUTE SHEET (RULE 26)

8/27

FIGURE 4A

ATG	AAA	CAG	ATT	AAG	GTT	CGA	GTG	GAC	ATG	CTG	CGG	CAT	AGA	ATC	45
Met	Lys	Gln	Ile	Lys	Val	Arg	Val	Asp	Met	Leu	Arg	His	Arg	Ile	15
1				5					10						
AAG	GAG	CAC	ATG	CTG	AAA	AAA	TAT	ACC	CAG	ACG	GAA	GAG	AAA	TTC	90
Lys	Glu	His	Met	Leu	Lys	Lys	Tyr	Thr	Gln	Thr	Glu	Glu	Lys	Phe	30
				20					25						
ACT	GGC	GCC	TTT	AAT	ATG	ATG	GGA	GGA	TGT	TTG	CAG	AAT	GCC	TTA	135
Thr	Gly	Ala	Phe	Asn	Met	Met	Gly	Gly	Cys	Leu	Gln	Asn	Ala	Leu	45
				35					40						
GAT	ATC	TTA	GAT	AAG	GTT	CAT	GAG	CCT	TTC	GAG	GAG	ATG	AAG	TGT	180
Asp	Ile	Leu	Asp	Lys	Val	His	Glu	Pro	Phe	Glu	Glu	Met	Lys	Cys	60
				50					55						
ATT	GGG	CTA	ACT	ATG	CAG	AGC	ATG	TAT	GAG	AAC	TAC	ATT	GTA	CCT	225
Ile	Gly	Leu	Thr	Met	Gln	Ser	Met	Tyr	Glu	Asn	Tyr	Ile	Val	Pro	75
				65					70						
GAG	GAT	AAG	CGG	GAG	ATG	TGG	ATG	GCT	TGT	ATT	AAG	GAG	CTG	CAT	270
Glu	Asp	Lys	Arg	Glu	Met	Trp	Met	Ala	Cys	Ile	Lys	Glu	Leu	His	90
				80					85						
GAT	GTG	AGC	AAG	GGC	GCC	GCT	AAC	AAG	TTG	GGG	GGT	GCA	CTG	CAG	315
Asp	Val	Ser	Lys	Gly	Ala	Ala	Asn	Lys	Leu	Gly	Gly	Ala	Leu	Gln	105
				95					100						
GCT	AAG	GCC	CGT	GCT	AAA	AAG	GAT	GAA	CTT	AGG	AGA	AAG	ATG	ATG	360
Ala	Lys	Ala	Arg	Ala	Lys	Lys	Asp	Glu	Leu	Arg	Arg	Lys	Met	Met	120
				110					115						
TAT	ATG	TGC	TAC	AGG	AAT	ATA	GAG	TTC	TTT	ACC	AAG	AAC	TCA	GCC	405
Tyr	Met	Cys	Tyr	Arg	Asn	Ile	Glu	Phe	Phe	Thr	Lys	Asn	Ser	Ala	135
				125					130						
TTC	CCT	AAG	ACC	ACC	AAT	GGC	TGC	AGT	CAG	GCC	ATG	GCG	GCA	TTG	450
Phe	Pro	Lys	Thr	Thr	Asn	Gly	Cys	Ser	Gln	Ala	Met	Ala	Ala	Leu	150
				140					145						
CAG	AAC	TTG	CCT	CAG	TGC	TCC	CCT	GAT	GAG	ATT	ATG	GCT	TAT	GCC	495
Gln	Asn	Leu	Pro	Gln	Cys	Ser	Pro	Asp	Glu	Ile	Met	Ala	Tyr	Ala	165
				155					160						
CAG	AAA	ATA	TTT	AAG	ATT	TTG	GAT	GAG	GAG	AGA	GAC	AAG	GTG	CTC	540
Gln	Lys	Ile	Phe	Lys	Ile	Leu	Asp	Glu	Glu	Arg	Asp	Lys	Val	Leu	180
				170					175						
ACG	CAC	ATT	GAT	CAC	ATA	TTT	ATG	GAT	ATC	CTC	ACT	ACA	TGT	GTG	585
Thr	His	Ile	Asp	His	Ile	Phe	Met	Asp	Ile	Leu	Thr	Thr	Cys	Val	195
				185					190						
GAA	ACA	ATG	TGT	AAT	GAG	TAC	AAG	GTC	ACT	AGT	GAC	GCT	TGT	ATG	630
Glu	Thr	Met	Cys	Asn	Glu	Tyr	Lys	Val	Thr	Ser	Asp	Ala	Cys	Met	210
				200					205						

SUBSTITUTE SHEET (RULE 20)

9/27

FIGURE 4B

ATG	ACC	ATG	TAC	GGG	GGC	ATC	TCT	CTC	TTA	AGT	GAG	TTC	TGT	CGG	675
Met	Thr	Met	Tyr	Gly	Gly	Ile	Ser	Leu	Leu	Ser	Glu	Phe	Cys	Arg	225
				215					220						
GTG	CTG	TCC	TGC	TAT	GTC	TTA	GAG	GAG	ACT	AGT	GTG	ATG	CTG	GCC	720
Val	Leu	Ser	Cys	Tyr	Val	Leu	Glu	Glu	Thr	Ser	Val	Met	Leu	Ala	240
				230					235						
AAG	CGG	CCT	CTG	ATA	ACC	AAG	CCT	GAG	GTT	ATC	AGT	GTA	ATG	AAG	765
Lys	Arg	Pro	Leu	Ile	Thr	Lys	Pro	Glu	Val	Ile	Ser	Val	Met	Lys	255
				245					250						
CGC	CGC	ATT	GAG	GAG	ATC	TGC	ATG	AAG	GTC	TTT	GCC	CAG	TAC	ATT	810
Arg	Arg	Ile	Glu	Glu	Ile	Cys	Met	Lys	Val	Phe	Ala	Gln	Tyr	Ile	270
				260					265						
CTG	GGG	GCC	GAT	CCT	CTG	AGA	GTC	TGC	TCT	CCT	AGT	GTG	GAT	GAC	855
Leu	Gly	Ala	Asp	Pro	Leu	Arg	Val	Cys	Ser	Pro	Ser	Val	Asp	Asp	285
				275					280						
CTA	CGG	GCC	ATC	GCC	GAG	GAG	TCA	GAT	GAG	GAA	GAG	GCT	ATT	GTA	900
Leu	Arg	Ala	Ile	Ala	Glu	Glu	Ser	Asp	Glu	Glu	Glu	Ala	Ile	Val	300
				290					295						
GCC	TAC	ACT	TTG	GCC	ACC	CGT	GGT	GCC	AGC	TCC	TCT	GAT	TCT	CTG	945
Ala	Tyr	Thr	Leu	Ala	Thr	Arg	Gly	Ala	Ser	Ser	Ser	Asp	Ser	Leu	315
				305					310						
GTG	TCA	CCC	CCA	GAG	TCC	CCT	GTA	CCC	GCG	ACT	ATC	CCT	CTG	TCC	990
Val	Ser	Pro	Pro	Glu	Ser	Pro	Val	Pro	Ala	Thr	Ile	Pro	Leu	Ser	330
				320					325						
TCA	GTA	ATT	GTG	GCT	GAG	AAC	AGT	GAT	CAG	GAA	GAA	AGT	GAG	CAG	1035
Ser	Val	Ile	Val	Ala	Glu	Asn	Ser	Asp	Gln	Glu	Glu	Ser	Glu	Gln	345
				335					340						
AGT	GAT	GAG	GAA	GAG	GAG	GAG	GGT	GCT	CAG	GAG	GAG	CGG	GAG	GAC	1080
Ser	Asp	Glu	Glu	Glu	Glu	Glu	Gly	Ala	Gln	Glu	Glu	Arg	Glu	Asp	360
				350					355						
ACT	GTG	TCT	GTC	AAG	TCT	GAG	CCA	GTG	TCT	GAG	ATA	GAG	GAA	GTT	1125
Thr	Val	Ser	Val	Lys	Ser	Glu	Pro	Val	Ser	Glu	Ile	Glu	Glu	Val	375
				365					370						
GCC	CCA	GAG	GAA	GAG	GAG	GAT	GGT	GCT	GAG	GAA	CCC	ACC	GCC	TCT	1170
Ala	Pro	Glu	Glu	Glu	Glu	Asp	Gly	Ala	Glu	Glu	Pro	Thr	Ala	Ser	390
				380					385						
GGA	GGC	AAG	AGC	ACC	CAC	CCT	ATG	GTG	ACT	AGA	AGC	AAG	GCT	GAC	1215
Gly	Gly	Lys	Ser	Thr	His	Pro	Met	Val	Thr	Arg	Ser	Lys	Ala	Asp	405
				395					400						
CAG	TAA														1221
Gln															

SUBSTITUTE SHEET (RULE 26)

10/27

FIGURE 5A

GCC	ATG	GCA	TCC	GTA	CTG	GGT	CCC	ATT	TCG	GGG	CAC	GTG	CTG	AAA	45
Met	Ala	Ser	Val	Leu	Gly	Pro	Ile	Ser	Gly	His	Val	Leu	Lys		
1				5					10						
	ATA														
	Ile														
GCC	GTG	TTT	AGT	CGC	GGC	GAC	ACG	CCG	GTG	CTG	CCG	CAC	GAG	ACG	90
Ala	Val	Phe	Ser	Arg	Gly	Asp	Thr	Pro	Val	Leu	Pro	His	Glu	Thr	
15					20					25					
						T									
CGA	CTC	CTG	CAG	ACG	GGT	ATC	CAC	GTG	CGC	GTG	AGC	CAG	CCC	TCG	135
Arg	Leu	Leu	Gln	Thr	Gly	Ile	His	Val	Arg	Val	Ser	Gln	Pro	Ser	
30					35					40					
							A								
CTG	ATC	CTG	GTG	TCG	CAG	TAC	ACG	CCC	GAC	TCG	ACG	CCA	TGC	CAC	180
Leu	Ile	Leu	Val	Ser	Gln	Tyr	Thr	Pro	Asp	Ser	Thr	Pro	Cys	His	
45					50					55					
		T		A											
CGC	GGC	GAC	AAT	CAG	CTG	CAG	GTG	CAG	CAC	ACG	TAC	TTT	ACG	GGC	225
Arg	Gly	Asp	Asn	Gln	Leu	Gln	Val	Gln	His	Thr	Tyr	Phe	Thr	Gly	
60					65					70					
AGC	GAG	GTG	GAG	AAC	GTG	TCG	GTC	AAC	[5' splice-donor GTG CAC AAC CCC ACG GGC Val His Asn Pro Thr Gly					270	
Ser	Glu	Val	Glu	Asn	Val	Ser	Val	Asn							
75					80					85					
CGG	AGC	ATC	TGC	CCC	AGC	CAA] 3' splice-acceptor GAG CCC ATG TCG ATC TAT GTG TAC Glu Pro Met Ser Ile Tyr Val Tyr							315	
Arg	Ser	Ile	Cys	Pro	Ser	Gln									
90					95					100					
							G								
GCG	CTG	CCG	CTC	AAG	ATG	CTG	AAC	ATC	CCC	AGC	ATC	AAC	GTG	CAC	360
Ala	Leu	Pro	Leu	Lys	Met	Leu	Asn	Ile	Pro	Ser	Ile	Asn	Val	His	
105					110					115					
CAC	TAC	CCG	TCG	GCG	GCC	GAG	CGC	AAA	CAC	CGA	CAC	CTG	CCC	GTA	405
His	Tyr	Pro	Ser	Ala	Ala	Glu	Arg	Lys	His	Arg	His	Leu	Pro	Val	
120					125					130					
GCT	GAC	GCT	GTG	ATT	CAC	GCG	TCG	GGC	AAG	CAG	ATG	TGG	CAG	GCG	450
Ala	Asp	Ala	Val	Ile	His	Ala	Ser	Gly	Lys	Gln	Met	Trp	Gln	Ala	
135					140					145					
CGT	CTC	ACG	GTC	TCG	GGA	CTG	GCC	TGG	ACG	CGT	CAG	CAG	AAC	CAG	495
Arg	Leu	Thr	Val	Ser	Gly	Leu	Ala	Trp	Thr	Arg	Gln	Gln	Asn	Gln	
150					155					160					

SUBSTITUTE SHEET (RULE 28)

11/27

FIGURE 5B

TGG	AAA	GAG	CCC	GAC	GTC	TAC	TAC	ACG	TCA	GCG	TTC	GTG	TTT	CCC	540
Trp	Lys	Glu	Pro	Asp	Val	Tyr	Tyr	Thr	Ser	Ala	Phe	Val	Phe	Pro	
165					170					175					
ACC	AAG	GAC	GTG	GCA	CTG	CGG	CAC	GTG	GTG	TGC	GCG	CAC	GAG	CTG	585
Thr	Lys	Asp	Val	Ala	Leu	Arg	His	Val	Val	Cys	Ala	His	Glu	Leu	
180					185					190					
GTT	TGC	TCC	ATG	GAG	AAC	ACG	CGC	GCA	ACC	AAG	ATG	CAG	GTG	ATA	630
Val	Cys	Ser	Met	Glu	Asn	Thr	Arg	Ala	Thr	Lys	Met	Gln	Val	Ile	
195					200					205					
GGT	GAC	CAG	TAC	GTC	AAG	GTG	TAC	CTG	GAG	TCC	TTC	TGC	GAG	GAC	675
Gly	Asp	Gln	Tyr	Val	Lys	Val	Tyr	Leu	Glu	Ser	Phe	Cys	Glu	Asp	
210					215					220					
GTG	CCC	TCC	GGC	AAG	CTC	TTT	ATG	CAC	GTC	ACG	CTG	GGC	TCT	GAC	720
Val	Pro	Ser	Gly	Lys	Leu	Phe	Met	His	Val	Thr	Leu	Gly	Ser	Asp	
225					230					235					
GTG	GAA	GAG	GAC	CTG	ACG	ATG	ACC	CGC	AAC	CCG	CAA	CCC	TTC	ATG	765
Val	Glu	Glu	Asp	Leu	Thr	Met	Thr	Arg	Asn	Pro	Gln	Pro	Phe	Met	
240					245					250					
CGC	CCC	CAC	GAG	CGC	AAC	GGC	TTT	ACG	GTG	TTG	TGT	CCC	AAA	AAT	810
Arg	Pro	His	Glu	Arg	Asn	Gly	Phe	Thr	Val	Leu	Cys	Pro	Lys	Asn	
255					260					265					
ATG	ATA	ATC	AAA	CCG	GGC	AAG	ATC	TCG	CAC	ATC	ATG	CTG	GAT	GTG	855
Met	Ile	Ile	Lys	Pro	Gly	Lys	Ile	Ser	His	Ile	Met	Leu	Asp	Val	
270					275					280					
GCT	TTT	ACC	TCA	CAC	GAG	CAT	TTT	GGG	CTG	CTG	TGT	CCC	AAG	AGC	900
Ala	Phe	Thr	Ser	His	Glu	His	Phe	Gly	Leu	Leu	Cys	Pro	Lys	Ser	
285					290					295					
ATC	CCG	GGC	CTG	AGC	ATC	TCA	GGT	AAC	CTA	TTG	ATG	AAC	GGG	CAG	945
Ile	Pro	Gly	Leu	Ser	Ile	Ser	Gly	Asn	Leu	Leu	Met	Asn	Gly	Gln	
300					305					310					
G															
CAG	ATC	TTC	CTG	GAG	GTG	CAA	GCG	ATA	CGC	GAG	ACC	GTG	GAA	CTG	990
Gln	Ile	Phe	Leu	Glu	Val	Gln	Ala	Ile	Arg	Glu	Thr	Val	Glu	Leu	
315					320					325					
A C															
CGT	CAG	TAC	GAT	CCC	GTG	GCT	GCG	CTC	TTC	TTT	TTC	GAT	ATC	GAC	1035
Arg	Gln	Tyr	Asp	Pro	Val	Ala	Ala	Leu	Phe	Phe	Phe	Asp	Ile	Asp	
330					335					340					

SUBSTITUTE SHEET (RULE 28)

12/27

FIGURE 5C

TTG	CTG	CTG	CAG	CGC	GGG	CCT	CAG	TAC	AGC	GAA	CAC	CCC	ACC	TTC	1080
Leu	Leu	Leu	Gln	Arg	Gly	Pro	Gln	Tyr	Ser	Glu	His	Pro	Thr	Phe	
345					350					355					
										G					
ACC	AGG	CAG	TAT	CGC	ATC	CAG	GGC	AAG	CTT	GAG	TAC	CGA	CAC	ACC	1125
Thr	Ser	Gln	Tyr	Arg	Ile	Gln	Gly	Lys	Leu	Glu	Tyr	Arg	His	Thr	
360					365					370					
TGG	GAC	CGG	CAC	GAC	GAG	GGT	GCC	GCC	CAG	GGC	GAC	GAC	GAC	GTC	1170
Trp	Asp	Arg	His	Asp	Glu	Gly	Ala	Ala	Gln	Gly	Asp	Asp	Asp	Val	
375					380					385					
TGG	ACC	AGC	GGA	TCG	GAC	TCC	GAC	GAG	GAA	CTC	GTA	ACC	ACC	GAG	1215
Trp	Thr	Ser	Gly	Ser	Asp	Ser	Asp	Glu	Glu	Leu	Val	Thr	Thr	Glu	
390					395					400					
A															
CGC	AAG	ACG	CCC	CGC	GTT	ACC	GGC	GGC	GGC	GCC	ATG	GCG	GGC	GCC	1260
Arg	Lys	Thr	Pro	Arg	Val	Thr	Gly	Gly	Gly	Ala	Met	Ala	Gly	Ala	
405					410					415					
					C										
TCC	ACT	TCC	GCG	GGC	CGC	AAA	CGC	AAA	TCA	GCA	TCC	TCG	GCG	ACG	1305
Ser	Thr	Ser	Ala	Gly	Arg	Lys	Arg	Lys	Ser	Ala	Ser	Ser	Ala	Thr	
420					425					430					
GCG	TGC	ACG	GCG	GGC	GTT	ATG	ACA	CGC	GGC	CGC	CTT	AAG	GCC	GAG	1350
Ala	Cys	Thr	Ala	Gly	Val	Met	Thr	Arg	Gly	Arg	Leu	Lys	Ala	Glu	
435					440					445					
					T										
					Ser										
TCC	ACC	GTC	GCG	CCC	GAA	GAG	GAC	ACC	GAC	GAG	GAT	TCC	GAC	AAC	1395
Ser	Thr	Val	Ala	Pro	Glu	Glu	Asp	Thr	Asp	Glu	Asp	Ser	Asp	Asn	
450					455					460					
GAA	ATC	CAC	AAT	CCG	GCC	GTG	TTC	ACC	TGG	CCG	CCC	TGG	CAG	GCC	1440
Glu	Ile	His	Asn	Pro	Ala	Val	Phe	Thr	Trp	Pro	Pro	Trp	Gln	Ala	
465					470					475					
GGC	ATC	CTG	GCC	CGC	AAC	CTG	GTG	CCC	ATG	GTT	GCT	ACG	GTT	CAG	1485
Gly	Ile	Leu	Ala	Arg	Asn	Leu	Val	Pro	Met	Val	Ala	Thr	Val	Gln	
480					485					490					
GGT	CAG	AAT	CTG	AAG	TAC	CAG	GAG	TTC	TTC	TGG	GAC	GCC	AAC	GAC	1530
Gly	Gln	Asn	Leu	Lys	Tyr	Gln	Glu	Phe	Phe	Trp	Asp	Ala	Asn	Asp	
495					500					505					

A

SUBSTITUTE SHEET (RULE 26)

13/27

FIGURE 5D

ATC TAC CGC ATC TTC GCC GAA TTG GAA GGC GTA TGG CAG CCC GCT	1575
Ile Tyr Arg Ile Phe Ala Glu Leu Glu Gly Val Trp Gln Pro Ala	
510 515 520	
GCG CAA CCC AAA CGT CGC CGC CAC CGG CAA GAC GCC TTG CCC GGG	1620
Ala Gln Pro Lys Arg Arg Arg His Arg Gln Asp Ala Leu Pro Gly	
525 530 535	
CCA TGC ATC GCC TCG ACG CCC AAA AAG CAC CGA GGT TGAGCCACCC	1666
Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg Gly	
540 545 550	
GCCGCGCACG CTTAGGACGA CTCTATAAAA ACCCACGTCC ACTCAGACAC	1716
A G	
GCGACTTTTG GCCGCCACAC CTGTCGCCGC TGCTATATTT GCGACAGTTG	1766
A A	
CCGGAACCCT TCCCGACCTC CCACGAAGAC CCGTTCACCT TTGCGCATCC	1816
CCTGACCCCC CCCCTCATCC CGCCTTCGCG ATG TCT CAG GCA TCG TCC TCG	1867
Met Ser Gln Ala Ser Ser Ser	
555	
T C A	
CCC GGT GAG GGA CCC TCG TCG GAA GCG GCC GCG ATC AGC GAG GCC	1912
Pro Gly Glu Gly Pro Ser Ser Glu Ala Ala Ala Ile Ser Glu Ala	
560 565 570	
Hind III	
GAA GCC GCC AGC GGA AGC TT	1932
Glu Ala Ala Ser Gly Ser	
575	

SUBSTITUTE SHEET (RULE 28)

14/27

FIGURE 6A

TAGATCACCG	ATAGAAATTT	ACACGAGGCC	ACGCCGGCCG	GCAACAGCCA	50
CTGGTTGCTG	AGTACGATAA	AGGGTAGCAC	AGTAAGCGTG	AGAAAATTAG	100
TAGAGTAGAG	GTTGGTCATG	TAAATGGTGG	GCGTCGAATA	GCCAAGCACG	150
CGATTTCGTGA	GCAGCTGCGT	GATCAACACT	ATGGCGTTAA	GTGGACCGCC	200
CACGAAGATG	ATGAATGTGT	TGAGTACGGC	TTCGGTGGTT	CGAATGGCGA	250
ATAGCGGCCC	TGTCATGTTG	CAAGTGTCAT	TGATGTGCGG	AGGAGTGTG	300
TTGCGGGTCT	GGGCGGAACA	GCACACGGGG	CGAAAAACA	GAAGAAACAA	350
>>>>>>					
GTCAGCGGCG	CTTAAAAGAA	AACCGCGTAT	CCGCCTCCGC	TATTAACTA	400
----->					
CCCCCCTCC	CTCTAGGTGG	GGCGCTCACC	GAGTTGTGGA	TGATGGTGTC	450
Sac II					
CATCGTGGGC	GAATAGCAGA	<u>CCGCGGGCGC</u>	AGTCCGGGGC	GACGACGCTT	500
CCGGGTTCTG	GAGAAAAGCC	AGC	ATG AGT TTG CAG TTT ATC GGT CTA CAG	550	
			Met Ser Leu Gln Phe Ile Gly Leu Gln		
		1	5		
CGG CGC GAT GTG GTA GCC CTG GTC AAC TTT CTG CGC CAT CTC ACG	595				
Arg Arg Asp Val Val Ala Leu Val Asn Phe Leu Arg His Leu Thr					
10 15 20					
CAA AAG CCC GAC GTG GAT CTC GAG GCA CAC CCC AAG ATC CTG AAA	640				
Gln Lys Pro Asp Val Asp Leu Glu Ala His Pro Lys Ile Leu Lys					
25 30 35					
AAA TGT GGC GAA AAA CGC CTG CAC CGG CGT ACG GTG CTG TTC AAC	685				
Lys Cys Gly Glu Lys Arg Leu His Arg Arg Thr Val Leu Phe Asn					
40 45 50					
GAG CTC ATG CTT TGG TTG GGA TAC TAC CGC GAG CTG CGT TTT CAC	730				
Glu Leu Met Leu Trp Leu Gly Tyr Tyr Arg Glu Leu Arg Phe His					
55 60 65					
AAC CCC GAC CTC TCC TCA GTG CTC GAG GAG TTC GAG GTG CGT TGC	775				
Asn Pro Asp Leu Ser Ser Val Leu Glu Glu Phe Glu Val Arg Cys					
70 75 80					
GTG GCC GTG GCG CGT CGC GGC TAC ACT TAC CCG TTC GGT GAT CGT	820				
Val Ala Val Ala Arg Arg Gly Tyr Thr Tyr Pro Phe Gly Asp Arg					
85 90 95					

SUBSTITUTE SHEET (RULE 2B)

15/27

FIGURE 6B

GGT	AAG	GCG	CGT	GAC	CAC	CTG	GCT	GTG	CTA	GAC	CGT	ACC	<u>GAA</u>	<u>TTC</u>	865
Gly	Lys	Ala	Arg	Asp	His	Leu	Ala	Val	Leu	Asp	Arg	Thr	Glu	Phe	
100					105					110					
GAT	ACG	GAC	GTG	CGC	CAC	GAT	GCC	GAG	ATC	GTG	GAA	CGC	GCG	CTC	910
Asp	Thr	Asp	Val	Arg	His	Asp	Ala	Glu	Ile	Val	Glu	Arg	Ala	Leu	
115					120					125					
GTA	AGC	GCG	GTC	ATT	CTG	GCC	AAG	ATG	TCG	GTG	CGC	GAG	ACG	CTG	955
Val	Ser	Ala	Val	Ile	Leu	Ala	Lys	Met	Ser	Val	Arg	Glu	Thr	Leu	
130					135					140					
GTC	ACA	GCC	ATC	GGC	CAG	ACG	GAA	CCC	ATC	GCC	TTT	GTG	CAC	CTC	1000
Val	Thr	Ala	Ile	Gly	Gln	Thr	Glu	Pro	Ile	Ala	Phe	Val	His	Leu	
145					150					155					
AAG	GAT	ACG	GAG	GTG	CAG	CGC	ATT	GAA	GAA	AAC	CTG	GAG	GGT	GTG	1045
Lys	Asp	Thr	Glu	Val	Gln	Arg	Ile	Glu	Glu	Asn	Leu	Glu	Gly	Val	
160					165					170					
CGC	CGT	AAC	ATG	TTC	TGC	GTG	AAA	CCG	CTC	GAC	CTT	AAC	CTG	GAC	1090
Arg	Arg	Asn	Met	Phe	Cys	Val	Lys	Pro	Leu	Asp	Leu	Asn	Leu	Asp	
175					180					185					
CGG	CAC	GCC	AAC	ACG	GCG	CTG	GTC	AAC	GCC	GTC	AAC	AAG	CTC	GTG	1135
Arg	His	Ala	Asn	Thr	Ala	Leu	Val	Asn	Ala	Val	Asn	Lys	Leu	Val	
190					195					200					
TAC	ACG	GGC	CGT	CTC	ATC	ATG	AAC	GTG	CGC	AGG	TCT	TGG	GAG	GAG	1180
Tyr	Thr	Gly	Arg	Leu	Ile	Met	Asn	Val	Arg	Arg	Ser	Trp	Glu	Glu	
205					210					215					
CTG	GAG	CGC	AAA	TGT	CTG	GCG	CGC	ATT	CAG	GAG	CGC	TGC	AAG	CTG	1225
Leu	Glu	Arg	Lys	Cys	Leu	Ala	Arg	Ile	Gln	Glu	Arg	Cys	Lys	Leu	
220					225					230					
CTG	GTC	AAG	GAG	CTG	CGC	ATG	TGC	CTT	TCC	TTT	GAT	TCC	AAC	TAC	1270
Leu	Val	Lys	Glu	Leu	Arg	Met	Cys	Leu	Ser	Phe	Asp	Ser	Asn	Tyr	
235					240					245					
TGT	CGC	AAT	ATC	CTC	AAG	CAC	GCC	GTG	GAA	AAC	GGC	GAC	TCG	GCC	1315
Cys	Arg	Asn	Ile	Leu	Lys	His	Ala	Val	Glu	Asn	Gly	Asp	Ser	Ala	
250					255					260					
GAC	ACG	CTG	TTG	GAG	CTG	CTC	ATC	GAG	GAC	TTT	GAT	ATC	TAC	GTG	1360
Asp	Thr	Leu	Leu	Glu	Leu	Leu	Ile	Glu	Asp	Phe	Asp	Ile	Tyr	Val	
265					270					275					

SUBSTITUTE SHEET (RULE 28)

16/27

FIGURE 6C

GAC AGC TTC CCA CAG TCG GCG CAC ACG TTT TTG GGC GCG CGC TCG	1405
Asp Ser Phe Pro Gln Ser Ala His Thr Phe Leu Gly Ala Arg Ser	
280 285 290	
CCG TCG TTG GAG TTT GAC GAT GAC GCC AAT CTC CTC TCG CTC GGC	1450
Pro Ser Leu Glu Phe Asp Asp Asp Ala Asn Leu Leu Ser Leu Gly	
295 300 305	
GGC GGT TCG GCC TTC TCG TCG GTA CCC AAG AAA CAT GTC CCC ACG	1495
Gly Gly Ser Ala Phe Ser Ser Val Pro Lys Lys His Val Pro Thr	
310 315 320	
CAG CCG CTG GAC GGC TGG AGC TGG ATC GCC AGT CCC TGG AAG GGA	1540
Gln Pro Leu Asp Gly Trp Ser Trp Ile Ala Ser Pro Trp Lys Gly	
325 330 335	
CAC AAA CCG TTC CGC TTC GAG GCC CAT GGT TCT CTG GCA CCG GCC	1585
His Lys Pro Phe Arg Phe Glu Ala His Gly Ser Leu Ala Pro Ala	
340 345 350	
GCC GAA GCC CAC GCT GCC CGT TCG GCG GCC GTC GGC TAT TAC GAC	1630
Ala Glu Ala His Ala Ala Arg Ser Ala Ala Val Gly Tyr Tyr Asp	
355 360 365	
GAA GAG GAA AAG CGT CGC GAG CGG CAG AAA CGG GTG GAC GAC GAG	1675
Glu Glu Glu Lys Arg Arg Glu Arg Gln Lys Arg Val Asp Asp Glu	
370 375 380	
GTG GTG CAG CGT GAG AAA CAG CAG CTG AAG GCT TGG GAG GAG AGG	1720
Val Val Gln Arg Glu Lys Gln Gln Leu Lys Ala Trp Glu Glu Arg	
385 390 395	
Pst I	
CAG CAG AAC <u>CTG CAG</u> CAA CGT CAG CAG CAA CCA CCG CCC CCG GCA	1765
Gln Gln Asn Leu Gln Gln Arg Gln Gln Gln Pro Pro Pro Pro Ala	
400 405 410	
CGT AAA CCG AGC GCC TCC CGG AGG CTC TTT GGC TCC AGT GCC GAT	1810
Arg Lys Pro Ser Ala Ser Arg Arg Leu Phe Gly Ser Ser Ala Asp	
415 420 425	
GAG GAC GAC GAC GAT GAT GAT GAC GAG AAA AAC ATC TTT ACG CCC	1855
Glu Asp Asp Asp Asp Asp Asp Asp Glu Lys Asn Ile Phe Thr Pro	
430 435 440	
ATC AAG AAA CCG GGA ACT AGC GGC AAG GGC GCC GCT AGT GGT GGC	1900
Ile Lys Lys Pro Gly Thr Ser Gly Lys Gly Ala Ala Ser Gly Gly	
445 450 455	
GGT GTT TCC AGC ATT TTC AGC GGC CTG TTA TCC TCG GGC AGT CAG	1945
Gly Val Ser Ser Ile Phe Ser Gly Leu Leu Ser Ser Gly Ser Gln	
460 465 470	

SUBSTITUTE SHEET (RULE 28)

17/27

FIGURE 6D

AAA Lys 475	CCG Pro	ACC Thr	AGC Ser	GGT Gly	CCC Pro 480	TTG Leu	AAC Asn	ATC Ile	CCG Pro	CAA Gln 485	CAA Gln	CAA Gln	CAG Gln	CGT Arg	1990
CAC His 490	GCG Ala	GCT Ala	TTC Phe	AGT Ser	CTC Leu 495	GTC Val	TCC Ser	CCG Pro	CAG Gln	GTG Val 500	ACC Thr	AAG Lys	GCC Ala	AGC Ser	2035
CCG Pro 505	GGA Gly	AGG Arg	GTC Val	CGT Arg	CGG Arg 510	GAC Asp	AGC Ser	GCG Ala	TGG Trp	GAC Asp 515	GTG Val	AGG Arg	CCG Pro	CTC Leu	2080
ACG Thr 520	GAG Glu	ACC Thr	AGA Arg	GGG Gly	GAT Asp 525	CTT Leu	TTC Phe	TCG Ser	GGC Gly	GAC Asp 530	GAG Glu	GAT Asp	TCC Ser	GAC Asp	2125
AGC Ser 535	TCG Ser	GAT Asp	GGC Gly	TAT Tyr	CCC Pro 540	CCC Pro	AAC Asn	CGT Arg	CAA Gln	GAT Asp 545	CCG Pro	CGT Arg	TTC Phe	ACC Thr	2170
GAC Asp 550	ACG Thr	CTG Leu	GTG Val	GAC Asp	ATC Ile 555	ACG Thr	GAT Asp	ACC Thr	GAG Glu	ACG Thr 560	AGC Ser	GCC Ala	AAA Lys	CCG Pro	2215
CCC Pro 565	GTC Val	ACC Thr	ACC Thr	GCG Ala	TAC Tyr 570	AAG Lys	TTC Phe	GAG Glu	CAA Gln	CCG Pro 575	ACG Thr	TTG Leu	ACG Thr	TTC Phe	2260
GGC Gly 580	GCC Ala	GGA Gly	GTT Val	AAC Asn	GTT Val 585	CCT Pro	GCT Ala	GGC Gly	GCC Ala	GGC Gly 590	GCT Ala	GCC Ala	ATC Ile	CTC Leu	2305
ACG Thr 595	CCG Pro	ACG Thr	CCT Pro	GTC Val	AAT Asn 600	CCT Pro	TCC Ser	ACG Thr	GCC Ala	CCC Pro 605	GCT Ala	CCG Pro	GCC Ala	CCG Pro	2350
ACA Thr 610	CCT Pro	ACC Thr	TTC Phe	GCG Ala	GGT Gly 615	ACC Thr	CAA Gln	ACC Thr	CCG Pro	GTC Val 620	AAC Asn	GGT Gly	AAC Asn	TCG Ser	2395
CCC Pro 625	TGG Trp	GCT Ala	CCG Pro	ACG Thr	GCG Ala 630	CCG Pro	TTG Leu	CCC Pro	GGG Gly	GAT Asp 635	ATG Met	AAC Asn	CCC Pro	GCC Ala	2440
AAC Asn 640	TGG Trp	CCG Pro	CGC Arg	GAA Glu	CGC Arg 645	GCG Ala	TGG Trp	GCC Ala	CTC Leu	AAG Lys 650	AAT Asn	CCT Pro	CAC His	CTG Leu	2485
GCT Ala 655	TAC Tyr	AAT Asn	CCC Pro	TTC Phe	AGG Arg 660	ATG Met	CCT Pro	ACG Thr	ACT Thr	TCC Ser 665	ACG Thr	GCT Ala	TCT Ser	CAA Gln	2530

SUBSTITUTE SHEET (RULE 28)

18/27

FIGURE 6E

AAC	ACC	GTG	TCC	ACC	ACC	CCT	CGG	AGG	CCG	TCG	ACT	CCA	CGC	GCC	2575
Asn	Thr	Val	Ser	Thr	Thr	Pro	Arg	Arg	Pro	Ser	Thr	Pro	Arg	Ala	
670					675					680					
GCG	GTG	ACA	CAA	ACA	GCG	TCT	CGG	GAC	GCC	GCT	GAT	GAG	GTT	TGG	2620
Ala	Val	Thr	Gln	Thr	Ala	Ser	Arg	Asp	Ala	Ala	Asp	Glu	Val	Trp	
685					690					695					
Pst I															
GCT	TTA	AGG	GAC	CAA	ACT	GCA	GAG	TCA	CCG	GTC	GAA	GAC	AGC	GAG	2665
Ala	Leu	Arg	Asp	Gln	Thr	Ala	Glu	Ser	Pro	Val	Glu	Asp	Ser	Glu	
700					705					710					
GAG	GAA	GAC	GAC	GAC	TCC	TCG	GAC	ACC	GGC	TCC	GTC	GTC	AGC	CTG	2710
Glu	Glu	Asp	Asp	Asp	Ser	Ser	Asp	Thr	Gly	Ser	Val	Val	Ser	Leu	
715					720					725					
GGA	CAC	ACA	ACA	CCG	TCG	TCC	GAT	TAC	AAC	AAC	GAC	GTC	ATT	TCG	2755
Gly	His	Thr	Thr	Pro	Ser	Ser	Asp	Tyr	Asn	Asn	Asp	Val	Ile	Ser	
730					735					740					
CCT	CCC	AGT	CAG	ACG	CCC	GAG	CAG	TCG	ACG	CCG	TCC	AGA	ATA	CGT	2800
Pro	Pro	Ser	Gln	Thr	Pro	Glu	Gln	Ser	Thr	Pro	Ser	Arg	Ile	Arg	
745					750					755					
AAA	GCT	AAG	TTA	TCG	TCT	CCA	ATG	ACG	ACG	ACA	TCC	ACG	AGC	CAG	2845
Lys	Ala	Lys	Leu	Ser	Ser	Pro	Met	Thr	Thr	Thr	Ser	Thr	Ser	Gln	
760					765					770					
AAA	CCG	GTG	CTG	GGC	AAG	CGA	GTC	GCG	ACG	CCG	CAC	GCG	TCC	GCC	2890
Lys	Pro	Val	Leu	Gly	Lys	Arg	Val	Ala	Thr	Pro	His	Ala	Ser	Ala	
775					780					785					
CGA	GCG	CAG	ACG	GTG	ACG	TCG	ACG	CCG	GTT	CAG	GGA	AGG	CTA	GAG	2935
Arg	Ala	Gln	Thr	Val	Thr	Ser	Thr	Pro	Val	Gln	Gly	Arg	Leu	Glu	
790					795					800					
AAA	CAG	GTG	TCG	GGC	ACG	CCG	TCG	ACG	GTA	CCC	GCC	ACG	CTG	TTG	2980
Lys	Gln	Val	Ser	Gly	Thr	Pro	Ser	Thr	Val	Pro	Ala	Thr	Leu	Leu	
805					810					815					
CAA	CCT	CAA	CCG	GCT	TCG	TCT	AAA	ACG	ACG	TCA	TCA	AGG	AAC	GTG	3025
Gln	Pro	Gln	Pro	Ala	Ser	Ser	Lys	Thr	Thr	Ser	Ser	Arg	Asn	Val	
820					825					830					
ACT	TCT	GGC	GCG	GGA	ACC	TCT	TCC	GCT	TCT	TCG	GCT	CGA	CAG	CCG	3070
Thr	Ser	Gly	Ala	Gly	Thr	Ser	Ser	Ala	Ser	Ser	Ala	Arg	Gln	Pro	
835					840					845					

SUBSTITUTE SHEET (RULE 26)

19/27

FIGURE 6F

TCA	GCC	TCG	GCG	TCC	GTT	TTG	TCG	CCC	ACG	GAG	GAT	GAT	GTC	GTG	3115
Ser	Ala	Ser	Ala	Ser	Val	Leu	Ser	Pro	Thr	Glu	Asp	Asp	Val	Val	
850					855					860					
TCC	CCC	GCC	ACA	TCG	CCG	CTG	TCC	ATG	CTT	TCG	TCA	GCC	TCT	CCG	3160
Ser	Pro	Ala	Thr	Ser	Pro	Leu	Ser	Met	Leu	Ser	Ser	Ala	Ser	Pro	
865					870					875					
TCC	CCG	GCC	AAG	AGT	GCC	CCC	CCG	TCT	CCG	GTG	AAA	GGC	CGG	GGC	3205
Ser	Pro	Ala	Lys	Ser	Ala	Pro	Pro	Ser	Pro	Val	Lys	Gly	Arg	Gly	
880					885					890					
AGC	CGC	GTC	GGT	GTT	CCT	TCC	TTG	AAA	CCT	ACT	TTG	GGC	GGC	AAG	3250
Ser	Arg	Val	Gly	Val	Pro	Ser	Leu	Lys	Pro	Thr	Leu	Gly	Gly	Lys	
895					900					905					
GCG	GTG	GTA	GGT	CGA	CCG	CCC	TCG	GTC	CCC	GTG	AGC	GGT	AGC	GCG	3295
Ala	Val	Val	Gly	Arg	Pro	Pro	Ser	Val	Pro	Val	Ser	Gly	Ser	Ala	
910					915					920					
CCG	GGT	CGC	CTG	TCC	GGC	AGC	AGC	CGG	GCC	GCC	TCG	ACC	ACG	CCG	3340
Pro	Gly	Arg	Leu	Ser	Gly	Ser	Ser	Arg	Ala	Ala	Ser	Thr	Thr	Pro	
925					930					935					
ACG	TAT	CCC	GCG	GTA	ACC	ACC	GTT	TAC	CCA	CCG	TCG	TCT	ACG	GCC	3385
Thr	Tyr	Pro	Ala	Val	Thr	Thr	Val	Tyr	Pro	Pro	Ser	Ser	Thr	Ala	
940					945					950					
AAA	AGC	AGC	GTA	TCG	AAT	GCG	CCG	CCT	GTG	GCC	TCC	CCC	TCC	ATC	3430
Lys	Ser	Ser	Val	Ser	Asn	Ala	Pro	Pro	Val	Ala	Ser	Pro	Ser	Ile	
955					960					965					
CTG	AAA	CCG	GGG	GCG	AGC	GCG	GCT	TTG	CAA	TCA	CGC	CGC	TCG	ACG	3475
Leu	Lys	Pro	Gly	Ala	Ser	Ala	Ala	Leu	Gln	Ser	Arg	Arg	Ser	Thr	
970					975					980					
GGG	ACC	GCC	GCC	GTA	GGT	TCC	CCC	GTC	AAG	AGC	ACG	ACG	GGC	ATG	3520
Gly	Thr	Ala	Ala	Val	Gly	Ser	Pro	Val	Lys	Ser	Thr	Thr	Gly	Met	
985					990					995					
AAA	ACG	GTG	GCT	TTC	GAC	CTA	TCG	TCG	CCC	CAG	AAG	AGC	GGT	ACG	3565
Lys	Thr	Val	Ala	Phe	Asp	Leu	Ser	Ser	Pro	Gln	Lys	Ser	Gly	Thr	
1000					1005					1010					
GGG	CCG	CAA	CCG	GGT	TCT	GCC	GGC	ATG	GGG	GGC	GCC	AAA	ACG	CCG	3610
Gly	Pro	Gln	Pro	Gly	Ser	Ala	Gly	Met	Gly	Gly	Ala	Lys	Thr	Pro	
1015					1020					1025					
TCG	GAC	GCC	GTG	CAG	AAC	ATC	CTC	CAA	AAG	ATC	GAG	AAG	ATT	AAG	3655
Ser	Asp	Ala	Val	Gln	Asn	Ile	Leu	Gln	Lys	Ile	Glu	Lys	Ile	Lys	
1030					1035					1040					

SUBSTITUTE SHEET (RULE 28)

20/27

FIGURE 6G

AAC ACG GAG GAA TAGTTAAGAA ACACACACGC AGACGTACTT TTTAATGAAA 3707
 Asn Thr Glu Glu
 1045

CCATCGGATA GTGACGTGTC GGGAAAGGAG GACGGACGGA GGGTCAGGGA 3757
 TGGGGAGACG TGAGAAAGTT GTCCGCGGGC AATTGCATGT CGCCCAGAAA 3807
 GAACGTGGTT GTTCCGGCGG CGTGCATCTG CCGAAACACC GTGTGGTGGT 3857
 TGTACGAGTA CACGTTACCG TCGCCCTCGG TAATTTGATA CAACGTGGCG 3907
 ATGGGGGTGC CCTGCGGGAT CACGATGGAA CGCGTGCGCG TCCACAGCGT 3957
 GACTTTGAGC GGCTCGCCGC CGCGCCACAC GCTGAGCCCC GTGTAAAAGG 4007
 CGTCCTCGTG TGGCAAGTTG GCCACCAAGA AACACCGGTC TGTGATCTGC 4057
 ACGTAGCGCA AGTCCAATC CACCGTCTGC CGCGGTTGCA CCCCAGAGTG 4107
 GATATCGTAA GGCGCGTGCA CCGTGAGCGA AAACACGTTG GGCTCATTGA 4157
 GAAGCGGACA GTTGAGCGCG TCGCCGCTAA AAAAGAGTGA CGGGTTGCGG 4207
 CTGAATCGCA GGTCGTACCC GCGCTGCGCG CTCGTCAGCA GGTAGAAGGA 4257
 AAAAGCGCGC GGCATGTTGC GCGCCGTGAT CTTGTCCGAG ACGCGGTGAC 4307
 AGAAGGAGGT GGCCACGGTG CCCAGCAGTT GCGCTGTTC CGCGTCCACG 4357

Eco RI

CATAGTGAAT CCACGTTGAC GGTGAAAATG AGACCCATGA ATTCGTACTG 4407
 CACGTTTTTG GACGCGATCC ACGCTTCGTC CTCGCCGGGT AGCGCTGCCT 4457
 CGTCGTCGTC CATCGTGCCG CGGAACTGCG CGAGGTAGCG CGTAATTTTT 4507
 TTGTGTCCGT ACGTGTTTAC GCGCTTACTG ATCCAGGTCA GATGGTCCAC 4557
 GCGACATAGC AGCGTCGCGC CATGCCGCGT GACGCTGACC CGTCCAAAGG 4607
 GCGCCGCCTC CTCCAACCCC GCAACGCCGC TCGGAGCACC GCCGCAGCCC 4657
 GGCTTTCCCG GCGTCGTGAA AGGCACGGCG TAATGCGGGC AGGCGTGCGG 4707
 CACGAAGGGC ACCATGACCA GTTGTGTGTG CAGAAAACCG ATCTGCACCG 4757
 CCTGCGACTG CCGCATGGTT TCCTCGTCGT AAACCGCCAT GGACGAGCAG 4807
 AGCCCGCCCT TGGTGATGAG CGGTTGCAGC ACCACGGAGC TCTCGCTGGT 4857

SUBSTITUTE SHEET (RULE 28)

21/27

FIGURE 6H

GGAGCAGAGC AGAAAGAAGA GCTCGGCGTA CGCCGCCTTG GCGGTCACCA	4907
CGTTGGACCA GTCGTA CTG TAGCCGCAGC CCTGCGTGTT GTTGTAATG	4957
ACGGGAAACG AGAGAAAGAT GCAGCCCTGC ACGTACGAAG <u>CTTTCTCCGT</u>	5007
CACGTTTCGAG GCCGTGTTGT ACTGCTCGGT GATGGACACC AAGTACGACT	5057
CGTAGGCCCGT CAGGTGCGAG GCCGAACGGT GAATCTTGGC GTGGCGCAGC	5107
CAGCGACCGT AGTTGTGCGC GTCCGCGTCG CGTAGCGCTT CGATCCACGA	5157
GGTCACCACG TCCTGCGCCG GCAGACGATA GTCCTGCTCG GGGTCCATGT	5207
GGCGGCACAG CCGCAGGCGC TCTGCCAGTT GGCAGGGGAT ACCGTCGTGC	5257
GACCTTTTGA CCGCGGTGGT GCCTGTCGTC CTCGTCTCCC CTCCTTCGTT	5307
CTCCCTGTTT TCTCTTCTCT CATTCCCGGT <u>CTCCGGATCC</u> GCAGCCGCTA	5357
CCTCTTGCTC CGCGGTTTTT TCGCCACCT CGCTCGTCGC TGTCGCCGCC	5407
ACCGCAGCGG CGGCGACGGA CGGCGGCGGT AACAACAGCT CCGTGAAGCT	5457
GACGAGCGGC AGCGGCGACG ACGGTGGCGG CGACGACACG GCGACGGTCA	5507
ACAGGGTCAC AAGCGTGGGT TTGTCCCCCA TAATCTGGTC GCCGCCACCG	5557
CCGTCGTTGC CGGTCCCCGT TTCCTCCGGC GTCGCGGTTT CCGCCGTCTC	5607
CGGATGAGCG GCCGCGGCGC GGGCTCGGCG TCCCGCCGTC CGAGACGGTG	5657
TATATAAACC GCGTCGGCCT CGCCGGCCCC AGCGCGCCGG GGAGAAGAAC	5707
CTCTTCCCCG GCCCCGCGTT CAAGACGGCG TGCCGTGACG CTCGATGGGT	5757
CCGCTTCATC AGACTGCGTA CGCTTTGGAG CGTCAGACCC AGGGCGCATG	5807
TAGCCGACTT GGAGGACTTT GCCGCCTTTT ATCGCACCCCT CTCGGACAGT	5857
GAGCAGCAGG AGTTCGAGCA AGAAGCCGAA CTCGCCTCCC GCTCACAACG	5907
CGTGCAACAC CTGCGCGAGG CCCGGCGCCA GCTCAAGATG GACCTGATGT	5957
GTCACGGCGG TTGAAAACGC GCATGATCTC GCGAAGCCAT CTACGCGCCT	6007
GTCAGGGCGA TGACGACATC AGCGATGACG GCTCCTGATA CGCGCCGGCA	6057

SUBSTITUTE SHEET (RULE 26)


22/27

FIGURE 6I

Pst I					
GCTGCAGCAC	GTGGAGACGC	TGCGTCGGTT	TCTGCGCGGC	GACAGCTGCT	6107
TTGTGCACGA	TCTCCCGGGC	ATGATGGACT	ATCACGACGG	GCTCTCGCGC	6157
CGTCAACAGC	GTGCCTTTTG	CCGCGCGAGT	CGCGTGTTGA	CGGACCCGGA	6207
<div style="text-align: center;"> ** **** -- </div>					
GCCCATCCAG	AGCGAAGCGG	AGGGGGAGAA	TAAACAGTTT	ACGGAGCACA	6257
<div style="text-align: center;"> -----J ***** --- </div>					
CACACAAAGT	AGTCTCGTTT	TTTATTAAAA	GTGTCTTTGT	ATTTCCCTAT	6307
<div style="text-align: center;"> ---J </div>					
CTTGTGTTGC	CCAACTGCTG	TCAGGTCTCC	GTAGATCGCT	CCCGGGTGCC CGA	6360

SUBSTITUTE SHEET (RULE 26)

23/27



2255-2920: hCMV IE1 enhancer/promoter
 2923-2951: Multiple cloning sites
 2952-3650: BGH terminator
 3651-4051 and 1-2254: pUC19

FIG. 7A

SUBSTITUTE SHEET (RULE 20)

24/27




FIG. 7B

SUBSTITUTE SHEET (RULE 28)

25/27




FIG. 7C

SUBSTITUTE SHEET (RULE 28)




FIG. 8

SUBSTITUTE SHEET (RULE 28)

27/27




FIG. 9

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/06866

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/38 C07K14/045 A61K39/245 C12N15/86 //A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GÖNCZÖL, E. ET AL.: "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate" VACCINE., vol. 13, 1995, GUILDFORD GB, pages 1080-1085, XP004057496	1,3,12, 16,17, 20-23, 26,27
Y	see the whole document	22,23, 26-28
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

18 September 1997

Date of mailing of the international search report

01.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/US 97/06866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BERENCSI, K. ET AL.: "The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response" VACCINE., vol. 14, April 1996, GUILDFORD GB, pages 369-374, XP004057290 cited in the application see the whole document ---	22,23, 26-28
X	EP 0 609 580 A (CHIRON CORP) 10 August 1994 see page 8, column 1 - column 45 see examples ---	1-3,12, 16,17, 21-23, 26,27
O,X	GONCZOL, E. ET AL.: "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate; immune response elicited in a prime/boost protocol with the glycoprotein B subunit." SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, SUPPLEMENT 99, 1995, (110-112)., XP002041029 see the whole document ---	1,3,12, 16,17, 21-23, 26,27
A	DHAWAN, J. ET AL.: "Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle" SOMATIC CELL AND MOLECULAR GENETICS, vol. 21, 1995, pages 233-240, XP002041030 cited in the application ---	
A	BERENCSI, K. ET AL.: "MURINE CYTOTOXIC T CELL RESPONSE SPECIFIC FOR HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B (GB) INDUCED BY ADENOVIRUS AND VACCINIA VIRUS RECOMBINANTS EXPRESSING GB" JOURNAL OF GENERAL VIROLOGY, vol. 74, 1993, pages 2507-2512, XP002026070 cited in the application ---	

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/06866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PANDE, H. ET AL.: "HUMAN CYTOMEGALOVIRUS STRAIN TOWNE PP65 GENE: NUCLEOTIDE SEQUENCE AND EXPRESSION IN ESCHERICHIA COLI" VIROLOGY, vol. 182, no. 1, May 1991, pages 220-228, XP000561310</p> <p style="text-align: center;">---</p>	
A	<p>GOSSEN M ET AL: "TIGHT CONTROL OF GENE EXPRESSION IN MAMMALIAN CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 12, 15 June 1992, pages 5547-5551, XP000564458</p> <p style="text-align: center;">---</p>	
A	<p>EP 0 252 531 A (BEHRINGWERKE AG) 13 January 1988</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Internatic application No.

PCT/US 97/06866

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 17-28
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 97/06866

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0609580 A	10-08-94	AU 641121 B	16-09-93
		AU 3041389 A	25-08-89
		DK 179290 A	28-09-90
		EP 0436537 A	17-07-91
		JP 2607712 B	07-05-97
		JP 3503478 T	08-08-91
		WO 8907143 A	10-08-89
		US 5547834 A	20-08-96

EP 0252531 A	13-01-88	AU 605155 B	10-01-91
		AU 7412887 A	17-12-87
		DE 3644924 A	14-04-88
		DE 3782867 A	14-01-93
		ES 2044881 T	16-01-94
		JP 62296893 A	24-12-87
